



Cite this: *Nat. Prod. Rep.*, 2024, 41, 1264

## Advances in the total synthesis of bis- and tris-indole alkaloids containing N-heterocyclic linker moieties

Kyra R. Dvorak<sup>a</sup> and Jetze J. Tepe<sup>b</sup> \*<sup>b</sup>

The past several years have seen an increase in the discovery and isolation of natural products of the indole alkaloid class. Bis- and tris-indole alkaloids are classes of natural products that have been shown to display diverse, potent biological activities. Of particular interest are bis- and tris-indole alkaloids containing N-heterocyclic linker moieties. It has been reported that more than 85% of biologically active compounds contain one or more heterocyclic moieties; of these, N-heterocycles have been identified as the most prevalent. The goal of this review is to provide a detailed overview of the recent advances in isolation and total synthesis of bis- and tris-indole alkaloids that contain N-heterocyclic linker moieties. The known biological activities of these natural products will also be discussed.

Received 13th March 2024

DOI: 10.1039/d4np00012a

rsc.li/npr

1. Introduction
2. Bis-indole alkaloids
  - 2.1 Imidazole and imidazoline linker moieties
    - 2.1.1. Topsentins and Spongotines
    - 2.1.2. Nortopsentins
  - 2.2 Imidazolinone linker moieties
    - 2.2.1. Rhopaladins
    - 2.2.2. Spongisoritins
    - 2.2.3. Violaceins
  - 2.3 Pyrrole and pyrrole-dione linker moieties
    - 2.3.1. Arcyriarubins
    - 2.3.2. Lycogarubins
    - 2.3.3. Lynamincins
  - 2.4 Piperazine, piperazinone, and pyridone linker moieties
    - 2.4.1. Dragmacidins
    - 2.4.2. Hamacanthins
    - 2.4.3. Fellutanines
  - 2.5 Pyridine and diazine linker moieties
    - 2.5.1. Hyrtinadine/Alocasin/Scalaridine
3. Tris-indole alkaloids
  - 3.1 Aromatic N-heterocyclic linker moieties
    - 3.1.1. Gelliusines
    - 3.1.2. Tricepyridinium
  - 3.2 Non-aromatic N-heterocyclic linker moieties
    - 3.2.1. Tulongicin

- 3.2.2. Araisamines
4. Conclusions
5. Author contributions
6. Conflicts of interest
7. Acknowledgements
8. Notes and references

### 1. Introduction

As their name suggests, indole alkaloids are natural products that contain one or more indole structural moieties. They are commonly isolated from a variety of marine sources, including sponges, tunicates, red algae, acorn worms, and symbiotic bacteria, and they represent the largest, and among the most complicated, class of the marine alkaloids.<sup>1</sup> Indole alkaloids have been shown to display diverse biological activities, including cytotoxic, antitumor, antiviral, antibacterial, and anti-inflammatory activities.<sup>2</sup> The structure, activity, and synthesis of indole alkaloids have been discussed in several reviews over the years.<sup>3</sup> The goal of this review is to provide a detailed overview on recent advances in isolation and total synthesis of bis- and tris-indole alkaloid natural products that contain N-heterocyclic linker moieties. These heterocyclic moieties are of particular interest as it has been reported that more than 85% of biologically active compounds contain one or more heterocyclic moieties with N-heterocycles being the most prevalent.<sup>4</sup> These heterocyclic moieties are of particular interest as it has been reported that more than 85% of biologically active compounds contain one or more heterocyclic moieties.<sup>5</sup> The biological activities of these natural products will also be discussed.

<sup>a</sup>Michigan State University, USA. E-mail: [dvorakky@msu.edu](mailto:dvorakky@msu.edu)

<sup>b</sup>University of Virginia, USA



## 2. Bis-indole alkaloids

### 2.1 Imidazole and imidazoline linker moieties

**2.1.1. Topsentins and Spongotines.** Topsentins and Spongotines are classes of marine alkaloid bis-indole natural products that contain characteristic 2-carbonylimidazole or 2-carbonylimidazoline linker moieties between their two indole fragments. The first few natural products that were discovered in these classes were Deoxytopsentin (Topsentin A) (**1a**), Topsentin (Topsentin B1) (**1b**), and Bromotopsentin (Topsentin B2) (**1c**). These three natural products were first isolated from Mediterranean marine sponge *Topsentia genitrix*.<sup>6</sup> The structures of these natural products were elucidated *via* spectroscopic methods, as shown in Fig. 1, and **1a–c** were identified as weakly cytotoxic for fish and for dissociated cells of the freshwater sponge *Ephydatia fluviatilis*.<sup>5</sup> After these initial discoveries, the structurally related analogues **1d–h** and **2a–e**, were isolated from various marine sponges, including *Spongosorites*,<sup>2,5,7,8</sup> *Hexadella*,<sup>9,10</sup> *Discodermia calyx*,<sup>11</sup> *Rhaphisia lacezie*,<sup>12</sup> and *Topsentia*.<sup>5,13</sup> Natural products of the Topsentin and Spongotine classes have been shown to possess cytotoxic, anticancer, antibacterial, antiviral, antifungal and anti-inflammatory activities.<sup>3,14</sup>

In addition to these previously discussed natural products, the most recently isolated natural product in the Spongotine class was Dihydrospogotone C (**3**), which was isolated as a single enantiomer in 2017 from the *Topsentia* sp. marine




Fig. 1 Chemical structures of Topsentin and Spongotine natural products (**1a–h**, **2a–e**, **3**) and the synthetic Topsentin analogue Hydroxytopsentin (**1i**).

sponge. Its structure was elucidated *via* spectroscopic methods. Both stereocenters were determined to have the *S*-stereochemistry configurations consistent with experimental and calculated circular dichroism (CD) data (MPW1PW91/6-31G(d,p)).<sup>13</sup> In addition, **3** displayed antibacterial activity toward *S. aureus* (MIC:  $3.7 \mu\text{g mL}^{-1}$ ), anti-HIV activity ( $\text{IC}_{50}$  (YU2):  $3.5 \mu\text{M}$ ;  $\text{IC}_{50}$  (HxB2):  $4.5 \mu\text{M}$ ), and displayed no evidence of cytotoxic activity toward mammalian cells.<sup>13</sup> Dihydrospogotone C (**3**) has yet to be accessed *via* total synthesis.

The first natural product of the Topsentin and Spongotine classes to be accessed *via* total synthesis was Deoxytopsentin (Topsentin A) (**1a**) by Braekman, J., *et al.* in 1988.<sup>15</sup> As shown in Scheme 1, 3-(bromoacetyl)indole (**4**) was reacted with 1,1-dimethylhydrazine in acidic conditions to afford the amine salt (**5**). Then, **5** was refluxed in isopropanol (IPA) to prompt migration of the methyl groups and elimination of dimethylamine to afford the imine intermediate **6**, which immediately dimerized to afford the imine **1a** in 27% yield from **5**.




Kyra R. Dvorak

Kyra Dvorak is currently a graduate student in Dr Jetze Tepe's lab at Michigan State University. Her research interests focus on the synthesis of nitrogen-containing heterocycles and their application in the total synthesis of bis- and tris-indole natural products and 20S proteasome modulation.



Jetze J. Tepe


Jetze J. Tepe is currently a professor of chemistry and director of drug discovery at the University of Virginia. Prior to his position at the University of Virginia, he was a professor of chemistry at Michigan State University. His research program is focused on the synthesis and biological evaluations of natural products and derivatives thereof, as leads for drug development.



Scheme 1 The first total synthesis of Deoxytopsentin (**1a**).









Scheme 4 Cross-coupling and late-stage lithiation approach to Topsentin (1b).

the imidazoline core, in which a keto-thioimidate (25a–c) fragment and diamine (29a–b) fragment were cyclized.<sup>21,22</sup> Intermediates 25a–c were synthesized in four steps from commercially available indole starting materials (22a–c) in good yields (Scheme 5). There were two different approaches for accessing the indolic diamine fragments (29a–b). The first approach was used to synthesize the indolic diamine (29a). In this approach, an indolic hydroxylamine intermediate (26a) underwent reductions and hydrogenolysis *via* hydrogen and



Scheme 6 The first enantioselective total synthesis of (S)-Spongatine A (2a).

Pearlman's catalyst to access the debenzylated intermediate in 90% yield. Then, the Boc protecting group was quantitatively removed under acidic conditions to access 29a.<sup>23</sup> The second approach was a little more step-intensive to access the indolic diamine intermediate 29b as it could not be synthesized *via* the hydrogenative method of 29a due to problematic dehydrohalogenation of indoles under hydrogenative conditions.<sup>23</sup> In order to avoid hydrogenation conditions, the 6-bromo-indolic hydroxylamine intermediate 26b was oxidized to 27 *via* MnO<sub>2</sub> and subsequently reacted with hydroxylamine



Scheme 5 Total syntheses of 1a, 1f–h, 2a–c and 2e.



hydrochloride to remove the benzyl group and reduced *via*  $TiCl_3$  to achieve **28** in high yields. From there, **28** was subjected to acidic conditions to remove the Boc group and access **29b** in 92% yield.<sup>22</sup> The desired natural products were then accessed *via* the key base-catalyzed imidazoline cyclization between **25a-c** and **29a-b**. This cyclization was carried out with either  $Et_3N$  or Amberlyst A21 resin to access the desired natural products (**2a** (74%), **2b** (46%), **2c** (65%), **2e** (72%)) and the natural product analogue (**2f** (63%)) in good yields. Then, the imidazoline cores of **2a-c**, **2e**, and **2f** were oxidized *via* IBX to the imidazole of Toposentins **1f** (78%), **1g** (34%), **1h** (90%), **1a** (91%), and Toposentin analogue **1j** (quant). This was the first total synthesis of Spongotine A-C (**2a-c**), Bromodeoxytoposentin (**1f**), Isobromodeoxytoposentin (**1g**), and Dibromodeoxytoposentin (**1h**).<sup>21,22</sup> The natural product analogue **1j** was also synthesized and could be de-methylated in the future with  $BBr_3$  to access Hydroxytoposentin (Scheme 5).

The first enantioselective total synthesis of Spongotine A (**2a**) was achieved *via* a key imidazoline cyclization between a keto-aldehyde fragment (**34**) and an optically active diamine fragment (**33**), as shown in Scheme 6.<sup>24</sup> First, **34** was synthesized in three steps from 1*H*-indole, *via* a keto-acyl chloride intermediate, according to literature procedures.<sup>25</sup> Fragment **33** was synthesized *via* Sharpless dihydroxylation of a 3-vinyl indole intermediate **30** to access (*R*)-**31** in high yield and enantioselectivity. Then, (*R*)-**31** underwent a stereospecific Mitsunobu reaction to access the diazide intermediate (*S*)-**32** in 95% yield, in which the (*S*)-stereochemistry was set *via* inversion of the chiral center. The diazide (*S*)-**32** was then reduced to access the optically active indolic diamine intermediate (*S*)-**33** in high yields with 98% ee. To synthesize the imidazoline core and achieve Spongotine A (**2a**), (*S*)-**33** and **34** underwent condensation, cyclization, and oxidation to the imidazoline *via* NCS. Subsequent removal of the tosyl protecting group with base achieved Spongotine A (**2a**) in 51% yield. Through these final steps, the stereochemistry was retained, allowing for the first enantioselective total synthesis of Spongotine A (**2a**).<sup>24</sup> In addition, the specific optical rotation of the synthesized (*S*)-Spongotine A (**2a**) matched that of the natural Spongotine A (**2a**), allowing for the establishment of its previously unknown absolute configuration as (*S*)-Spongotine A.

**2.1.2. Nortopsentins.** The Nortopsentin class of bis-indole natural products are structurally similar to those of the Toposentin class, however, they lack a carbonyl moiety on the imidazole linker moiety, as shown in Fig. 2. Nortopsentin A (**35a**), B (**35b**), and C (**35c**) were first isolated from *Spongisorites ruetzleri* in 1987.<sup>26</sup> Nortopsentins A-C (**35a-c**) were found to possess cytotoxic and antifungal activities. Interestingly, the methylated derivatives of **35a-c** also displayed enhanced cytotoxic activity in P388 cells compared to the isolated natural products.<sup>26</sup> In addition, the unnatural synthetic Nortopsentin analogue **35d**, unfortunately also referred to as Nortopsentin D in several early literature reports, was accessed *via* hydrogenation of **35a-c**, as indole readily undergo de-halogenation under hydrogenation conditions.<sup>27</sup> Several years later, in 1996, the more complex structural variant of this class, Nortopsentin D (**36**), composed of a tri-substituted imidazolinone ((4*H*)-





Fig. 2 Chemical structures of Nortopsentins A–D (**35a–c**, **36**) and Nortopsentin synthetic analogue (**35d**).

imidazol-4-one) core, was first isolated from the axinellid sponge, *Dragmacidon* sp.<sup>28</sup> Later, **36** was also isolated from the sponge *Agelas dendromorpha*.<sup>29</sup> It is interesting to mention that the methylated derivative of **36** was also shown to have antifungal activity against yeast and high cytotoxicity toward tumoral cells.<sup>28,30</sup>

The first total syntheses of Nortopsentins A–C (**35a–c**), as well as the synthetic analogue **35d**, were achieved *via* a successive Pd-catalyzed cross-couplings of indole fragments to the imidazole core, as shown in Scheme 7.<sup>30</sup> The synthetic analogue **35d** was the first of these to be accessed *via* successive cross coupling reactions of a tri-brominated imidazole (**38**) with an *N*-TBS-protected indole-3-boronic acid (**37a**), using  $Pd(PPh_3)_4$  as a catalyst. The protecting groups and remaining bromide were then removed to access **35d** in high yields. During route development, SEM- and MOM-protecting groups were also explored for **37a**, yet the TBS-protecting group resulted in the highest yield of the coupling reaction.<sup>30</sup> More recently, an adapted method for palladium-catalyzed cross coupling of unprotected imidazoles was developed and utilized in the synthesis of **35d**, as shown in Scheme 7.<sup>31</sup> This Suzuki–Miyaura cross-coupling method allowed for a significantly expedited approach toward **35d**, as compared to previous reports. However, this method is likely only efficient for natural products bearing symmetrical indole moieties. In a similar manner, the first total syntheses of Nortopsentin A (**35a**) and C (**35c**) were achieved, as shown in Scheme 7. The efficient synthesis of **35c** was very similar to that of **35d**. Iodide was utilized as a coupling partner here, rather than bromide. Iodide was likely used here to prevent potential selectivity issues given the bromide substituents on the boronic acid coupling partners. The other major difference was the removal of the additional iodide before the second indole coupling (Scheme 7, synthesis of **35c**). It is noteworthy to mention that the selective de-iodination to access intermediate **43** was confirmed *via* a NOESY correlation between the SEM group on the nitrogen and the C5–H of the imidazole.<sup>30</sup> The approach toward the first total synthesis of Nortopsentin A (**35a**) and Nortopsentin B (**35b**), which also bear bromide substituents on their indoles, implemented a later stage iodination approach in the synthesis of **46** before the second cross coupling reaction to access **35a** and **35b** in moderate and good yield, respectively (Scheme 7).<sup>30</sup>






Scheme 7 The first total syntheses of Nortopsentin A–C (35a–c), and the Nortopsentin synthetic analogue (35d).


In addition to these cross-coupling approaches, a different non-cross-coupling approach was used to access the Nortopsentin natural products **35b** and **35d**. This method utilized the condensation of a nitrile with an  $\alpha$ -amino-ketone fragment and subsequent cyclization and aromatization of the imidazole at high temperatures to achieve Nortopsentin B (**35b**) and the Nortopsentin D synthetic analogue **35d** in good yields (Scheme 8).<sup>17</sup> This method was not viable for the total synthesis of Nortopsentins A (**35a**) and C (**35c**). This was likely due to the necessary hydrogenation step for the synthesis of intermediate **48**, which would not tolerate a bromide substituent on the indole (**48**), as has been previously discussed.

The first total synthesis of the more structurally complex Nortopsentin D (**36**) was completed by K. Keel, *et al.*, in 2021, as shown in Scheme 9.<sup>32</sup> The complex tri-substituted imidazolone ((4*H*)-imidazol-4-one) core was constructed *via* a late-stage Pinacol-like rearrangement. Two key fragments were utilized in



Scheme 8 Syntheses of Nortopsentin B (**35b**) and its synthetic analogue (**35d**) *via* thermal condensation–cyclization.

this approach; an alkyne fragment (**49**) and amidine fragment (**51**). The alkyne (**49**) and amidine (**51**) were accessed in two and five steps, respectively from the commercially available 6-bromo-1*H*-indole.<sup>32</sup> The alkyne fragment (**49**) was oxidized to the di-ketone intermediate (**50**) *via* mercuric nitrate monohydrate. The key condensation–cyclization and subsequent



Scheme 9 First total synthesis of Nortopsentin D (**36**).






Fig. 3 Chemical structure of Rhopaladins A–D (**53a–d**).


Pinacol-like rearrangement steps were then carried out to form the tri-substituted imidazolinone core of Nortopsentin D (**36**), accessing **52** in 52% yield. The *N*-tosyl and *N*-boc protecting groups were deprotected during this reaction. Precise deprotection was key for optimization, as successful cyclization was dependent upon electronics. It was found that the *N*-boc protecting group of **51** had to first be deprotected to allow for sufficient nucleophilicity of the amidine (**51**) to condense and cyclize with the di-ketone (**50**). The presence of the *N*-tosyl protecting group of **50** was also found to contribute to increased electrophilicity of the ketone. Therefore, initial acidic conditions were implemented to remove the *N*-boc group of **51**, followed by the strategic use of a mildly nucleophilic base and solvent to allow for cyclization to occur prior to de-tosylation of **50** (Scheme 9). After removal of the remaining protecting group to access the 2-amino-imidazole substituent, Nortopsentin D (**36**) was accessed in 70% yield.<sup>32</sup>

## 2.2 Imidazolinone linker moieties


**2.2.1. Rhopaladins.** Natural products of the Rhopaladin class are bis-indole alkaloids comprised of two indole fragments connected by an imidazolinone ((4*H*)-imidazol-4-one) linker moiety, similar to Nortopsentin D (**36**). In addition, the

indolylcarbonyl substitution at the C-2 position of the imidazolinone core is similar to the Spongotine and Topsentin natural product classes (Fig. 3). However, unlike any of the previously discussed natural product classes, the second indole moiety is connected at the 5-position of the imidazolinone core by a unique vinyl chain. Rhopaladins A–D (**53a–d**) were first isolated in 1998 by Sato *et al.* from the marine tunicate *Rhopalaea* sp.<sup>33</sup> The geometry of the alkene present in these natural products (**53a–d**) was identified as (*Z*) by a NOESY experiment that was run on Rhopaladin C (**53d**). The studies identified various NOESY correlations, such as a NOESY correlation between the two C-2 hydrogens of the indole moieties, indicating a (*Z*) geometry of the alkene. In terms of biological activities, these natural products were reported to demonstrate antibacterial activity against *Sarcina lutea* and *Corynebacterium xerosis* and inhibitory activity against cyclin dependent kinase 4 and c-erbB-2 kinase. However, their broader biological activity has yet to be explored.<sup>33</sup>

The first total synthesis of Rhopaladin D (**53d**) was reported in 2000, in which a key intermolecular aza-Wittig reaction was utilized, followed by subsequent condensation and cyclization to form the imidazolinone core of **53d**.<sup>34</sup> To perform the aza-Wittig reaction, the azide intermediate (**56**) was first accessed in three steps in high yields from indolyl-3-aldehyde **54** (Scheme 10). Then, the aza-Wittig reaction was performed on azide intermediate **56** to access intermediate **57**, which was immediately condensed and cyclized with keto-acyl chloride **23a** to access imidazolinone **58** in 56% yield over two steps. Lastly, the protecting group was removed to afford Rhopaladin D (**53d**) in 60% yield. However, **58** was isolated as a 6 : 4 mixture of *E/Z* isomers and after chromatographic separation, the (*Z*) isomer isomerized to the (*E*) isomer upon sunlight irradiation. Therefore, after the last step, Rhopaladin D (**53d**) was also isolated as a mixture of *E/Z* isomers.<sup>34</sup>



Scheme 10 First total synthesis of Rhopaladin D (**53d**).



Scheme 11 Total syntheses of Rhopaladins A–D (**53a–d**).






Fig. 4 Chemical structures of Spongisoritins A–D (**64a–d**).

A couple years later, the total syntheses of all four Rhopaladins A–D (**53a–d**) were achieved *via* a key imidate-based cyclization with tryptophan esters to form the imidazolinone core of these natural products, as shown in Scheme 11.<sup>35</sup> First, the carbonyl nitrile intermediate (**60a–b**) was synthesized *via* a TMS-cyanohydrin intermediate from aldehyde **59a–b**, followed by subsequent oxidation to the carbonyl nitrile **60a–b** in high yields. Then, **60a–b** underwent a Pinner reaction with gaseous hydrochloric acid and ethanol to form the imidate intermediate (**61a–b**). Compounds **61a–b** were immediately condensed and cyclized with tryptophan methyl ester hydrochloride (**62a**) in the presence of triethylamine to access Rhopaladin C (**53b**) and D (**53d**) in 38% and 35% yield, respectively. Interestingly, the dehydrogenation to form the alkene of the Rhopaladins occurs spontaneously after the cyclization has occurred. This is likely due to the highly conjugated nature of the Rhopaladins, contributing to high stability. Interestingly, this cyclization and spontaneous dehydrogenation specifically produced (*Z*)-isomers of the Rhopaladins, as was confirmed *via* NOESY correlations, including a NOESY correlation between the C2–H's of the indole moieties. The presence of the (*E*)-isomers could not be detected.<sup>35</sup> Thus, this method was proven to be very selective to the (*Z*)-isomer, which is a major advantage compared to the previous synthesis of Rhopaladin D (**53d**). Rhopaladins A and B (**53a** and **53b**) were synthesized in the same manner as Rhopaladin C and D (**53c** and **53d**), as shown in Scheme 11. The only difference was the identity of the tryptophan methyl ester (**62b**). In addition, after the key cyclization reaction and spontaneous dehydrogenation to access **63a** and **63b**, an additional de-methylation step *via* BBr<sub>3</sub> was required to access Rhopaladins A (**53a**) and B (**53b**) in 81% and 62% yields, respectively. In addition, similarly to **53c** and **53d**, the Rhopaladins A (**53a**) and B (**53b**) were confirmed with NOESY as the desired (*Z*)-isomer.<sup>35</sup>




Fig. 5 Chemical structures Violacein (**65a**) and related natural product analogues (**65b–g**).

**2.2.2. Spongisoritins.** Recently, the first of the Spongisoritins were isolated, which marks another natural product class to contain an imidazolinone (2,3-dihydro-4*H*-imidazol-4-one) core. Spongisoritins A–D (**64a–d**) were first isolated in 2021 from *Spongisorites* sp. by Park, *et. al.*<sup>36</sup> As shown in Fig. 4, the chemical structure of the Spongisoritins contains one indole moiety and one indolyl-3-ketone moiety connected by a 2-methoxy-1-imidazole-5-one linker. These chemical structures were elucidated *via* spectroscopic methods. In addition, these Spongisoritins (**64a–d**) contain one stereocenter at the C-2 position of the imidazolinone. The absolute configuration of this position was determined *via* a density functional theory (DFT)-based computational method and electronic circular dichroism (ECD). Comparing measured data with the calculated data, the stereochemistry was assigned as a (2*R*) configuration.<sup>36</sup>


Initial biological activity exploration of the Spongisoritins (**64a–d**) was conducted and it was found that they exhibited moderate inhibition against transpeptidase sortase A and weak inhibition against human pathogenic bacteria and A549 and K562 cancer cell lines. The biological activity findings are detailed in Table 1, including the known antibiotic, ampicillin, for comparison.<sup>36</sup> Though some information is now known, much of the Spongisoritins' biological activities remain elusive. Furthermore, Spongisoritins A–D (**64a–d**) have yet to be accessed *via* total synthesis.

**2.2.3. Violaceins.** Natural products of the Violacein class are purple-blue pigments produced from bacteria, unlike many other bis-indole natural products which come from marine

Table 1 Biological activity of Spongisoritins A–D (**64a–d**)

#	Gram (+) MIC (μg mL <sup>-1</sup> )			Gram (–) MIC (μg mL <sup>-1</sup> )			IC <sub>50</sub> (μM)		
	<i>S. aureus</i>	<i>Enterococcus faecalis</i>	<i>Enterococcus faecium</i>	<i>Klebsiella pneumonia</i>	<i>Salmonella enterica</i>	<i>E. coli</i>	Srt A	A549	K562
64a	>128	>128	>128	>128	>128	>128	>329.8	77.3	24.2
64b	64	>128	>128	128	128	>128	62.7	55.7	28.2
64c	32	128	>128	>128	64	>128	43.9	61.2	37.7
64d	16	120	120	>128	64	>128	>274.7	70.9	54.2
Ampicillin	0.13	0.5	1	—	0.25	8			






Scheme 12 Total syntheses of Violacein (**65a**) and Deoxyviolacein (**65b**).

sponges and tunicates. Violacein (**65a**) was first discovered in 1882 by Boisbaudran, *et. al.*<sup>37</sup> Natural products of the Violacein class (**65a–g**) have been isolated from several Gram-negative bacteria, including *Chromobacterium violaceum*, *Janthionobacterium lividum*, *Pseudoalteromonas luteoviolacea*, *Pseudomonas sp.*, *Collimonas sp.*, *Dunganelia*, etc.<sup>38–42</sup> As shown in Fig. 5, the structure of the Violacein natural products consist of three main sub-classes, the Violaceins (**65a–c**), whose two indole moieties are connected by a 1,3-dihydro-2*H*-pyrrol-2-one core linker, the Protoviolaceinic acids (**65d–e**), whose two indole moieties are connected by a pyrrole-2-carboxylic acid linker, and the Proviolaceins (**65f–g**), which contain a 2*H*-pyrrol-2-one core. These various sub-classes are produced from the same biosynthetic pathway, either as related paths or as intermediates toward one another.<sup>43</sup> In addition, these natural products exhibit significant biological activity, such as antibacterial, antifungal, anti-cancer, antiviral, and antiparasitic activity.<sup>44</sup>

Natural products of the Violacein class (**65a–g**) have been most widely accessed *via* exploration of biosynthetic pathways.<sup>43</sup>




Scheme 13 Total syntheses of Violacein (**65a**) and Deoxyviolacein (**65b**).

However, these biosynthetic pathways fall outside the scope of this review. Progress has also been made toward the total synthesis of these compounds. The first total synthesis of Violacein and Deoxyviolacein was achieved by Ballantine, *et. al.*<sup>45</sup> *via* a key reaction of the lactone intermediates **66a** or **66b** with ammonia under heating to replace the oxygen atom of the lactone with a nitrogen atom to afford the desired 1,3-dihydro-2*H*-pyrrol-2-one core of Deoxyviolacein (**65b**) and imidazolinone intermediate (**67**) in good yields, as is shown in Scheme 12. Violacein was then accessed after an additional de-methylation step of **67** to complete the first total synthesis of Violacein (**65a**).<sup>45</sup>

Violacein and Deoxyviolacein were also accessed *via* total synthesis in 2001, in which Steglich, *et. al.* implemented a strategy where the two indole groups were attached stepwise to an already formed pyrrolinone core, as shown in Scheme 13.<sup>46</sup> First, pyrrolinone **68** underwent an acid-catalyzed reaction with **22a** or **22d**, and subsequent protection of both the nitrogens *via* Boc-anhydride, to access intermediates **69a–b** in high yields. Then, **69a–b** were converted to their corresponding enolates using LiHMDS as the base, followed by subsequent reaction with *N*-Boc-isatin (**70**) to afford the aldol condensation intermediates (**71a–b**). Then, **71a–b** were immediately heated to afford Deoxyviolacein (**65b**) and intermediate **72** in 30% and 24%, respectively. It is noteworthy to mention that upon adsorption to silica gel and heating for 15–20 minutes, dehydration, dehydrogenation, and cleavage of the Boc-protecting groups all occurred simultaneously. Lastly, **72** underwent debenzoylation to access Violacein (**65a**) in 82% yield. The configurations of **65a–b** were confirmed as (*E*)-isomers *via* NMR.<sup>48</sup> This approach was advantageous as it was significantly higher yielding than the first reported total synthesis of these natural products (**65a–b**).

A more recent approach used a tandem ring-closing metathesis (RCM)/isomerization/nucleophilic addition



Scheme 14 Total synthesis of Violacein (**65a**) *via* a tandem RCM/isomerization/nucleophilic addition sequence.






Fig. 6 Chemical structures of Arcyriarubins A–C (**76a–c**) and Dihydroarcyriarubins A–B (**77a–b**).

sequence toward the total synthesis of Violacein, as shown in Scheme 14.<sup>47</sup> This tandem RCM/isomerization/nucleophilic addition was the first step used in the total synthesis, followed by elimination to intermediate **74** in good yields. The oxindole moiety was then attached *via* a Ti-catalyzed tautomerization/aldol condensation with isatin to access **75** in high yield. After acid-mediated removal of protecting groups, Violacein (**65a**) was achieved in 49% yield. The authors mentioned that the final product **65a** was very difficult to handle and had very minimal solubility in common solvents. Therefore, it was suspected that the crude yield was significantly higher than the isolated yield.<sup>47</sup>

### 2.3 Pyrrole and pyrrole-dione linker moieties


**2.3.1. Arcyriarubins.** Arcyriarubins A–C (**76a–c**) are bisindolylmaleimides first isolated by Steglich, *et. al.* in 1980 from the red sporangia of the slime mold *Arcyria denudate*.<sup>48</sup> Arcyriarubins B (**76b**) and C (**76c**) were also isolated from *Tubifera casparyi* in 2003 by Ishibashi, *et. al.*<sup>49</sup> The chemical structure (Fig. 6) of these compounds was elucidated by spectroscopic means. Arcyriarubins A–C (**76a–c**) contain two indole moieties linked by a pyrrole-2,5-dione (maleimide) core. These natural products display moderate antibiotic, antifungal, cytotoxic, and kinase inhibition activities.<sup>48,49</sup> These natural products are also of great interest, as many structurally related bisindolylmaleimides are selective protein kinase C (PKC) inhibitors, which show promise as novel potential therapeutics for autoimmune diseases.<sup>50,51</sup>

In addition, two structurally related natural products that have also been isolated include Dihydroarcyriarubins B (**77a**) and C (**77b**). As shown in Fig. 6, these natural products are incredibly similar to the Arcyriarubins (**76a–c**), however, the reduced pyrrolidine-2,5-dione (succinimide) core of the Dihydroarcyriarubins (**77a–b**) sets them apart. Dihydroarcyriarubin B (**77a**) was first isolated by Steglich, *et. al.* from the slime mold, *Arcyria denudate*, alongside the Arcyriarubins (**76a–b**).<sup>48</sup> Dihydroarcyriarubin C (**77b**) was first isolated in 2003 by Ishibashi, *et. al.* from *Arcyria ferruginae*, alongside Arcyriarubin C (**76b**).<sup>49</sup> The biological activities of the Dihydroarcyriarubins B (**77a**) and C (**77b**) are very similar to that of **76a–c**, including antibiotic, antifungal, cytotoxic, and kinase inhibition activities.<sup>48,49,52</sup>

The first natural products of the Arcyriarubin class to be accessed *via* total synthesis were Arcyriarubin A (**76a**) and Arcyriarubin B (**76b**) in 1988 by Steglich, *et. al.*<sup>53</sup> These total


syntheses were accomplished using Grignard reactions to install the indole moieties on the maleimide core, as shown in Scheme 15. In the first total synthesis of Arcyriarubin A (**76a**), a Grignard reaction was carried out *via* an indole Grignard reagent and 3,4-dibromo-*N*-methylmaleimide to access bisindolylmaleimide intermediate (**78**) in high yield. To remove the methyl group of **78**, a maleic anhydride intermediate (**79**) was accessed and then subsequently reacted with ammonium acetate at high temperatures to access Arcyriarubin A (**76a**) in high yields.<sup>53</sup> Due to the asymmetric nature of the indole moieties in Arcyriarubin B (**76b**), the synthetic approach to this natural product was slightly different. As shown in Scheme 15, the first total synthesis of **76b** was achieved *via* a reaction of an indole Grignard reagent (**77b**) with a mono-indolic maleimide intermediate (**80**) to access intermediate **81** in 89% yield. This approach allowed for the synthesis of a maleimide intermediate with asymmetric indole moieties (**81**) in a stepwise manner. After de-methylation and removal of protecting groups, Arcyriarubin B (**76b**) was accessed in high yield.<sup>53</sup>

Several years later, a similar Grignard approach to the total synthesis of Arcyriarubin A (**76a**) was utilized in 1995 (Scheme



Scheme 15 Total synthesis of Arcyriarubins A–B (**76a–b**).





Scheme 16 Total synthesis of Arcyriarubin A (76a).



15).<sup>54</sup> Here, an indole Grignard (**83**) was reacted with 3,4-dichloromaleimide (**84a**) at high temperature to access Arcyriarubin A (**76a**) in 72% yield. This approach was advantageous in that it allowed for the synthesis of Arcyriarubin A (**76a**) without the need for protecting groups, which greatly expediting its synthesis.<sup>54</sup> However, the intolerance for asymmetric indole moieties in this method makes it unsuitable for application to other Arcyriarubins. This Grignard strategy was again slightly improved upon in 2017 for the total synthesis of Arcyriarubin A (**76a**), as shown in Scheme 15.<sup>55</sup> Utilizing the same indole Grignard (**83**) and 3,4-dibromomaleimide (**84b**) at a higher temperature, for a shorter reaction time, Arcyriarubin A (**76a**) was synthesized in 78% yield.<sup>55</sup> It is also noteworthy to mention that Arcyriarubin C (**76c**) has yet to be accessed *via* total synthesis.

In addition to this Grignard approach, a more biomimetic approach has also been explored toward the total synthesis of Arcyriarubin A (**76a**), as shown in Scheme 16. This approach consisted of a base-mediated condensation-cyclization reaction between an indole-3-acetamide intermediate (**85**) and an indole-3-oxo-acyl chloride intermediate (**86a**) to access Arcyriarubin A (**76a**), although in a low 11% yield. Recently, an adapted and

improved biomimetic total synthesis of Arcyriarubin A (**76a**) was developed, as shown in Scheme 16. For this approach, intermediate **85** was condensed and cyclized with an indole-3-oxo-ester intermediate (**86b**) to access Arcyriarubin A (**76a**) in an excellent 96% yield.<sup>56</sup>


In terms of the Dihydroarcyriarubins (**77a–b**), Dihydroarcyriarubin B (**77a**) has yet to be accessed *via* total synthesis. On the other hand, the first total synthesis of Dihydroarcyriarubin C (**77b**) was completed in 2007 by Ishibashi, *et. al.*, as shown below in Scheme 17.<sup>52</sup> First, the bis-indolyl-*N*-methylmaleimide intermediate (**87**) was synthesized in four steps from 3,4-dibromomaleimide and 6-benzyloxyindole, following the same Grignard approach as was previously published by Steglich, *et. al.*<sup>53</sup> To remove the *N*-methyl group, intermediate **87** was converted to the maleic anhydride intermediate (**88**), which was subsequently reacted with ammonium acetate at high temperatures to access the bis-indolylmaleimide intermediate (**89**) in very high yields. Then, **89** underwent hydrogenation to reduce the maleimide core of **89** to the succinimide core of Dihydroarcyriarubin C (**77b**). In addition to the desired reduction of **89**, both benzyl groups were also removed. While this was beneficial for the total synthesis of Dihydroarcyriarubin C (**77b**); it was also the reason why this approach was not viable for synthesizing Arcyriarubin C (**76c**). It is noteworthy to mention that at a 12 hours hydrogenation reaction time, *cis*-Dihydroarcyriarubin C (**77b**) was accessed in 95% yield, but at a 5 hours reaction time, *trans*-Dihydroarcyriarubin C (**77b**) was accessed in 98% yield. In addition, *cis*-Dihydroarcyriarubin C (**77b**) could be isomerized to *trans*-Dihydroarcyriarubin C (**77b**) either by magnesium in methanol or DBU in tetrahydrofuran in 81% and 93% yield, respectively. To accomplish the first total synthesis of Dihydroarcyriarubin C (**77b**), both the *cis*-**77b** and *trans*-**77b** isomers were synthesized to allow for the stereochemical determination of the isolated Dihydroarcyriarubin C (**77b**). Comparison of their NMR data allowed for confirmation of the isolated **77b** as *trans*-Dihydroarcyriarubin C (**77b**).<sup>52</sup>

**2.3.2. Lycogarubins.** Lycogarubins A–C (**90a–c**) and Lycogolic acid (**90d**) were first isolated independently by Steglich, *et. al.* and Asakawa, *et. al.* from *Lycogala epidendrum*, a slime mold (Myxomycetes).<sup>57,58</sup> Lycogolic Acid (**90d**) has also been referred to as chromopyrrolic acid (CPA). The chemical structures of these natural products were elucidated *via* spectroscopic analysis. As shown below in Fig. 7, the two indole moieties of these


Scheme 17 Total synthesis of Dihydroarcyriarubin C (**77b**).

Lycogarubin A (**90a**): R<sup>1</sup>=Me, R<sup>2</sup>=OH, R<sup>3</sup>=OH  
 Lycogarubin B (**90b**): R<sup>1</sup>=Me, R<sup>2</sup>=H, R<sup>3</sup>=OH  
 Lycogarubin C (**90c**): R<sup>1</sup>=Me, R<sup>2</sup>=R<sup>3</sup>=H  
 Lycogolic Acid (**90d**): R<sup>1</sup>=R<sup>2</sup>=R<sup>3</sup>=H

Fig. 7 Chemical structures of Lycogarubins A–C (**90a–c**) and Lycogolic acid (**90d**).




Scheme 18 Total synthesis of Lycogarubin C (90c).



Scheme 19 Biomimetic total syntheses of Lycogarubin C (90c) and Lycagolic acid (90d).

bis-indole natural products are linked by a pyrrole-2,5-methyl ester core in Lycogarubins A–C (90a–c) or a pyrrole-2,5-carboxylic acid core in Lycagolic acid (90d). These natural products closely resemble the previously discussed Arcyriarubin natural products (76a–c), differing mainly in the aromatic pyrrole core of 90a–d rather than the maleimide core of 76a–c. Much of the biological activity of these natural products is unexplored, though Lycogarubin C displayed moderate anti-HSV-I virus activity.<sup>58</sup> In addition, these compounds are of interest due to their structural similarity to potent kinase inhibitors.<sup>52</sup>

Many of the early syntheses of the Lycogarubins (90a–c) and Lycagolic acid (90d) were carried out *via* the exploration of the biosynthetic pathway to these natural products.<sup>59</sup> However, the first of these natural products to be accessed *via* total synthesis was Lycogarubin C (90c) using a palladium-catalyzed Suzuki coupling reaction of dimethyl 3,4-dibromo-1H-pyrrole-2,5-dicarboxylate (91) with an indole-3-boronic acid (92) and subsequent removal of the protecting group *via* TBAF to access Lycogarubin C (90c) in 81% yield, as shown in Scheme 18.<sup>35</sup> This Suzuki method has been implemented in recent literature as



Scheme 20 Total synthesis of Lycogarubin C (90c).


well in the synthesis of 90c and similar structures.<sup>60</sup> Considering the ongoing study of the biosynthesis of the Lycogarubin natural products, several biomimetic syntheses have been developed as well. One of the earliest of these was completed in 2006 in which a methyl 3-(1H-indol-3-yl)-2-oxopropanoate intermediate (93) underwent a dimerization/cyclization sequence over three steps to access Lycogarubin C (90c) in 42% yield (Scheme 19).<sup>59,61</sup>

Another biomimetic synthesis of Lycogarubin C (90c), as well as Lycagolic acid (90d), was carried out *via* a Cu/Mn co-oxidized dimerization/cyclization of a Tosyl-tryptophan methyl ester (94) with another molecule of itself (Scheme 19). It is noteworthy to mention that biosynthesis of the Lycogarubins also begins with tryptophan starting materials. After removal of the protecting groups, Lycogarubin C (90c) was accessed in high yields. Lycogarubin C (90c) was then converted to Lycagolic acid (90d) in 95% yield *via* base-catalyzed ester hydrolysis.<sup>62</sup>


Recently, a semi-total synthesis of Lycogarubin C (90c) was completed *via* Lycagolic acid (90d) as an intermediate (Scheme 19). First, enzymatic biological reactions were conducted to accomplish the dimerization/cyclization of the L-Tryptophan (L-Trp) starting material to access Lycagolic acid (90d). Then, 90d was immediately reacted with TMSCHN<sub>2</sub> in methanol to access Lycogarubin C (90c) in 69% over two steps from the simple and readily accessible L-Trp starting material.<sup>63</sup>

Another synthetic method that has been used to synthesize Lycogarubin C (90c) and Lycagolic acid (90d) was the use of key Diels–Alder and Kornfeld–Boger ring contraction reactions. One example utilizing this method, as shown in Scheme 20, began with the synthesis of the di-protected-bis-indole alkene intermediate (97) *via* a Wittig reaction between the bromide intermediate (95) and the aldehyde intermediate (96). Then, 97 underwent a Diels–Alder reaction with the tetrazine intermediate (98), followed by a subsequent Kornfeld–Boger ring






Scheme 21 Total syntheses of Lycogarin C (90c) and Lycagolic acid (90d).



Scheme 22 Total synthesis of Lynamycin D (104d).



Lynamycin A (104a): R<sup>1</sup>=H, R<sup>2</sup>=COOMe, R<sup>3</sup>=Cl, R<sup>4</sup>=H, R<sup>5</sup>=H  
 Lynamycin B (104b): R<sup>1</sup>=H, R<sup>2</sup>=COOMe, R<sup>3</sup>=Cl, R<sup>4</sup>=Cl, R<sup>5</sup>=H  
 Lynamycin C (104c): R<sup>1</sup>=H, R<sup>2</sup>=H, R<sup>3</sup>=Cl, R<sup>4</sup>=Cl, R<sup>5</sup>=Cl  
 Lynamycin D (104d): R<sup>1</sup>=COOMe, R<sup>2</sup>=COOMe, R<sup>3</sup>=Cl, R<sup>4</sup>=H, R<sup>5</sup>=H  
 Lynamycin E (104e): R<sup>1</sup>=COOMe, R<sup>2</sup>=COOMe, R<sup>3</sup>=H, R<sup>4</sup>=H, R<sup>5</sup>=Cl  
 Lynamycin F (104f): R<sup>1</sup>=H, R<sup>2</sup>=COOMe, R<sup>3</sup>=Cl, R<sup>4</sup>=H, R<sup>5</sup>=H, R<sup>6</sup>=Me  
 Lynamycin G (104g): R<sup>1</sup>=R<sup>2</sup>=COOMe, R<sup>3</sup>=Cl, R<sup>4</sup>=H, R<sup>5</sup>=H, R<sup>6</sup>=Me

Fig. 8 Chemical structures of Lynamycin A–G (104a–g).

contraction to access the pyrrole intermediate (99) in 54% yield over two steps. After removal of the protecting groups, Lycogarin C (90c) was accessed in 91% yield. Protection of both indole moieties was necessary to access intermediate 99 in good yields and to avoid side product formation *via* the Diels-Alder/Kornfeld-Boger reaction sequence.<sup>64</sup>

Another example in which this method was implemented, as shown in Scheme 21, began with the Diels-Alder reaction between 98 and 1,2-bis-(tributylstannyl)-acetylene to access diazine intermediate (100) in very high yield. Stille coupling of 100 with the 3-iodo-indole intermediate (101) and a subsequent Kornfeld-Boger ring contraction of the diazine core led to the desired pyrrole core of 103 in good yields. Then, 103 could be subjected to LiOH or KOH to access Lycogarin C (90c) or Lycagolic acid (90d), respectively, in very high yields. Furthermore, Lycogarin C (90c) could also be converted to Lycagolic acid (90d) *via* KOH in very high yields.<sup>65</sup> This approach (Scheme 21) is favorable in comparison to the previously discussed Diels-Alder/Kornfeld Boger approach (Scheme 20), as it not only allowed for the total synthesis of Lycogarin C (90c) in good


yields, but also allowed for the total synthesis of Lycagolic acid (90d) in good yields.

**2.3.3. Lynamycins.** More recently, a class of natural products that is structurally related to the Lycogarubins (90a–d) was discovered. In 2008, Lynamycins A–E (104a–e) were isolated by Potts, *et al.* from a novel marine actinomycete, of the proposed genus *Marinispora*. The chlorinated bis-indole chemical structures linked by a pyrrole moiety, as shown in Fig. 8, was confirmed in these natural products *via* spectroscopic methods.<sup>66</sup> Not only were these natural products (104a–e) the first examples of bis-indole pyrrole alkaloids bearing chloride substituents, but the Lynamycins A–E (104a–e) have also been found to display broad-spectrum antibiotic activity against both Gram-positive and Gram-negative bacteria, such as *Staphylococcus aureus* and *Enterococcus faecium*.<sup>66</sup> The Lynamycins have also been shown to possess anticancer and kinase inhibition activity.<sup>67</sup>

Two additional natural products of the Lynamycin class, Lynamycin F (104f) and Lynamycin G (104g), were isolated in 2014 by Zhang, *et al.*<sup>68</sup> from the deep-sea-derived actinomycete, *Streptomyces* sp. The chemical structures of Lynamycin F (104f) and Lynamycin G (104g), as shown in Fig. 8, were elucidated *via* spectroscopic methods. The characteristic *N*-methyl group in 104f and 104g was confirmed *via* key HMBC correlations between the hydrogens on the methyl group and the C-2 and C-5 carbons of the pyrrole ring. Interestingly, the presence of this methyl group seems to have a significant effect on biological activity because, unlike Lynamycins A–E (104a–e), Lynamycin F (104f) and Lynamycin G (104g) showed no significant antibiotic activity against *Staphylococcus aureus*, *Escherichia coli*, *etc.* and no significant cytotoxic activity toward cancer cell lines.<sup>68</sup>

The first of the Lycogarin class to be accessed *via* total synthesis was Lynamycin D (104d) by Nikolakaki, *et al.* in 2017, which utilized a Suzuki coupling approach to install the two







Scheme 23 Total synthesis of Lynamycin A (104a).

indole moieties to the pyrrole core.<sup>68</sup> As shown in Scheme 22, first, the 3,4-dibromopyrrole intermediate **106** was initially synthesized in two steps from the corresponding pyrrole-2-methylester in good yields. An indolic boronic ester intermediate (**105**) then underwent a palladium-catalyzed Suzuki reaction with **106** to access intermediate **107** in 76% yield. After removal of the Boc protecting groups *via* acidic conditions, Lynamycin D (**104d**) was achieved in 97% yield.<sup>68</sup> Recently, a semi-total synthesis of Lynamycin D (**104d**), resembling that of Lycogarubin C (**90c**), was also completed (Scheme 22).<sup>63</sup> First, enzymatic biological reactions were conducted to accomplish the dimerization/cyclization of the 5-chloro-L-Tryptophan (5-Cl-L-Trp) starting material (**108**), following the biosynthetic path, to access the carboxylic acid analogue of Lynamycin D (**109**). Then, **109** was immediately reacted with TMSCHN<sub>2</sub> in MeOH to access Lynamycin D (**104d**) in 37% over two steps from the simple 5-Cl-L-Trp (**108**) starting material.<sup>63</sup>

The first total synthesis of Lynamycin A (**104a**) was completed in 2021 by Smith, *et. al.*, as well as a slightly adapted total synthesis of Lynamycin D (**104d**).<sup>69</sup> As shown in Scheme 23, these total syntheses follow a very similar Suzuki cross-coupling to that of Nikolakaki's previously discussed method to install the indole moieties onto the pyrrole core of these natural products.<sup>67</sup> However, the Suzuki cross coupling step between the boronic ester intermediate (**110**) and the 3,4-dibromo pyrrole intermediate (**106**) utilized different palladium catalysts, as shown in Scheme 23, and featured a subsequent deprotection of the protecting groups to access Lynamycin D (**104d**) in 67% yield. Then, Lynamycin D (**104d**) was subjected to a basic environment, at high temperatures, which led to the removal of



(*Cis*)-Dragmacidin (**111**): R<sup>1</sup>=H, R<sup>2</sup>=Me, R<sup>3</sup>=OH, R<sup>4</sup>=Br  
*Trans*-Dragmacidin A (**111a**): R<sup>1</sup>=Me, R<sup>2</sup>=R<sup>3</sup>=R<sup>4</sup>=H  
*Trans*-Dragmacidin B (**111b**): R<sup>1</sup>=R<sup>2</sup>=Me, R<sup>3</sup>=R<sup>4</sup>=H  
*Cis*-Dragmacidin C (**111c**): R<sup>1</sup>=R<sup>2</sup>=R<sup>3</sup>=R<sup>4</sup>=H

Fig. 9 Chemical structures of Dragmacidin (**111**) and Dragmacidins A–C (**111a–c**).Fig. 10 Chemical structures of Dragmacidins D–G (**111d–g**).


one of the ester groups on the pyrrole ring, accessing Lynamycin A (**104a**) in 67% yield.<sup>69</sup> Lynamycins B, C, and E–G (**104b, c, e–g**) have yet to be accessed *via* total synthesis.

## 2.4 Piperazine, piperazinone, and pyridone linker moieties

**2.4.1. Dragmacidins.** The Dragmacidin class of natural products consists of two main structural sub-classes. The first sub-class consists of Dragmacidin (**111**) and Dragmacidins A–C (**111a–c**), which are bis-indole alkaloids whose two indole moieties are linked by a piperazine core, as shown in Fig. 9. Dragmacidin was first isolated in 1988, by Koehn *et. al.*, from *Dragmacidon* marine sponge.<sup>70</sup> A couple years later, Dragmacidin A (**111a**) and Dragmacidin B (**111b**) were isolated from *Hexadella* marine sponge.<sup>10</sup> The chemical structure of these natural products was elucidated *via* spectroscopic methods. Dragmacidin (**111**) and Dragmacidins A–B (**111a–b**) were confirmed to have *trans* configurations.<sup>10,71</sup> Dragmacidin C (**111c**) was the last of this sub-class to be discovered and was first isolated in 1991, by Smith, *et. al.*, from the sea squirt *Didemnum candidum*.<sup>71</sup> Dragmacidin C (**111c**) was initially thought to have *trans* configuration, but it was later shown to be of *cis* configuration.<sup>72</sup> The biological activities of Dragmacidin (**111**) and Dragmacidins A–C (**111a–c**) are relatively unexplored; however, Dragmacidin (**111**) and Dragmacidin A (**111a**) have been found to display significant cytotoxicity against a variety of cancer cell lines.<sup>70</sup>

The second sub-class of the Dragmacidins is comprised of more structurally complex natural products, including Dragmacidins D (**111d**), E (**111e**), and F (**111f**). These bis-indole natural products (**111d–f**) contain a 2-pyridone core that links their two indole, or modified indole, moieties, as shown in Fig. 10. Another structural distinction of this sub-class is the presence of a guanidine moiety. Dragmacidin D (**111d**) and Dragmacidin E (**111e**) were isolated in 1988 by Carroll, *et. al.* from *Spongisorites* and *Hexadella* marine sponges and their structures were elucidated *via* spectroscopic means.<sup>73</sup> In






Scheme 24 First total synthesis of Dragmacidin (111).

addition, Dragmacidin D (**111d**) and Dragmacidin E (**111e**) were found to be potent inhibitors of serine–threonine protein phosphatases.<sup>73</sup> Dragmacidin F (**111f**) was isolated a couple years later, in 2000, by Riccio, *et. al.* from a *Halicortex* marine sponge. The complex ring structure of Dragmacidin F (**111f**) was elucidated *via* extensive spectroscopic analysis and its unprecedented carbon skeleton was proposed to result from the cyclization of a partially oxidized form of Dragmacidin D (**111d**). Dragmacidin F (**111f**) was found to display antiviral activity against HSV-1 and HIV-1.<sup>74</sup> Dragmacidin E (**111e**) and Dragmacidin F (**111f**) have both been accessed *via* total synthesis; however, these syntheses will not be discussed in detail as these chemical structures fall outside the scope of this review.<sup>75,76</sup>

Recently, Dragmacidin G was isolated by Wright, *et. al.* from *Spongisorites* marine sponge. As is shown in Fig. 10, the chemical structure of Dragmacidin G (**111g**) does not exactly fit into the second sub-class of the Dragmacidins, as it is the only natural product in its class to contain a piperazine (1,4-diazine) core linking the two indole moieties. However, Dragmacidin G (**111g**) does contain a characteristic guanidine moiety, thus enabling it to still be considered part of the second structural sub-class of the Dragmacidins. In addition, Dragmacidin G (**111g**) was found to exhibit antibacterial activity against *Staphylococcus aureus*, *Mycobacterium tuberculosis*, *Plasmodium falciparum*, *etc.*, and cytotoxic activity against a panel of pancreatic cell lines.<sup>77</sup> Dragmacidin G has yet to be accessed *via* total synthesis.

Dragmacidin (**111**) was the first natural product of this class to be accessed *via* total synthesis. In 1994, Wuonola *et. al.* completed the first racemic total synthesis of Dragmacidin (**111**) *via* an initial condensation of an oxo-acyl chloride (**112**) and an amino nitrile (**113**) (synthesized *via* a Strecker method), followed by subsequent oxidation and cyclization, as shown in Scheme 24. These transformations proceeded in high yields.



Scheme 25 First total synthesis of Dragmacidin B (111b).


The cyclized intermediate was then subjected to reductive conditions to access **115a** and **115b**. This reduction, specifically the loss of the hydroxyl group, was not stereoselective at room temperature, resulting in a ratio of (**115a**:**115b** = 1:1). However, significant selectivity in favor of the desired *trans* isomer (**115b**) was achieved by lowering the temperature to  $0^\circ\text{C}$  for this reduction reaction, as shown in Scheme 24, resulting in 37% of the *trans* isomer (**115b**) compared to 9% of the undesired *cis* isomer (**115a**). Then, **115b** was de-methylated to afford Dragmacidin (**111**).<sup>78</sup>

The first total synthesis of Dragmacidin B (**111b**) was achieved in the same year as Dragmacidin (**111**). However, considering its less substituted indole moieties, the approach toward Dragmacidin B (**111b**) was less step intensive, as shown in Scheme 25. First, an *N*-dimethylated piperazinedione (**116**) was brominated before undergoing a double nucleophilic attack with 6-bromo-1*H*-indole to access intermediate **117** in 57% yield. The bromination and nucleophilic attacks were conducted in a one-pot manner and no acid or base was necessary for the nucleophilic step. Then, **117** was reduced to access Dragmacidin B (**111b**) in moderate yield. This made for a very expeditious two-step approach to complete the total synthesis of Dragmacidin B (**111b**) in 14% yield overall (Scheme 25).<sup>79</sup>

The first total synthesis of Dragmacidin A (**111a**) was completed in 2000 *via* a condensation/cyclization sequence of methylated (**118**) and free (**119**) indolic  $\alpha$ -amino carboxylic acids to access the piperazinedione intermediate (**121**) in good yields, as shown in Scheme 26. The condensation step was diastereoselective and the desired isomer (**120b**) predominated. After the cyclization, the carbonyl groups of intermediate (**121a**) were removed *via* reductive conditions to access Dragmacidin A (**111a**) in 45% yield. The total yield of Dragmacidin A (**111a**) after this efficient three-step approach was 21% overall.<sup>80</sup>

The first total synthesis of Dragmacidin C (**111c**) was completed in 2002 *via* the same three step method (condensation/cyclization/oxidation) that was previously discussed for the first total synthesis of Dragmacidin A (**111a**), and the relative *cis* configuration of Dragmacidin C (**111c**) was confirmed (Scheme 26). As shown in Scheme 26, Dragmacidin B (**111b**) was also synthesized using this method, though incomplete reduction of **121b** resulted in a prominent side product in which one carbonyl remained on the ring. This accounts for the lower yield of **122**. In the synthesis of Dragmacidin B (**111b**) a late-stage methylation step was carried out on the piperazine







Scheme 26 Total syntheses of Dragmacidins A–C (111a–c).

intermediate (**122**) to install the two methyl groups on the piperazine ring of Dragmacidin B (**111b**).<sup>72</sup>

Optically active Dragmacidin A (**111a**) was synthesized *via* a Sharpless asymmetric aminohydroxylation of 6-bromo-3-vinylindole (**30**) to access **124** in 65% yield and 94% enantiomeric excess, as shown in Scheme 27. The hydroxyl group of **124** was then tosylated and subsequently substituted by an azido group in high yield over two steps. The resulting amino azide intermediate (**125**) was then deprotected and acylated with **23b**, followed by reduction of the azide and subsequent cyclization to afford **127**. After Boc-protection, **127** was selectively and quantitatively methylated and subsequently deprotected to afford **128**. The reduction of intermediate **128** proved to be problematic, as it was nonselective. In fact, the desired isomer (**129**) was the minor product in just 17% isolated yield (82% of *cis* isomer isolated). Despite this low yield, **129** was de-tosylated *via* *l*-selectride and the piperazinone was reduced to the desired piperazine core to access (*2S*, *5R*)-Dragmacidin A (**111a**) in 42% yield over two steps.<sup>81</sup>


Scheme 27 First total synthesis of optically active Dragmacidin (**111**).

An expedited method of synthesizing optically active Dragmacidin A (**111a**) was developed in which a bis-indolylpyrazine intermediate (**131**) was protected and subsequently reduced to



Scheme 28 Total syntheses of Dragmacidins A–C (111a–c).





Scheme 29 First total synthesis of Dragmacidin D (111d).

the corresponding piperazine intermediate (132) in high yields, as shown in Scheme 28. Then, de-symmetrization of the piperazine (132) was completed *via* enantioselective formylation using a chiral formylating reagent. This method ultimately proved to be only moderately stereoselective, affording the dextrorotatory isomer of Dragmacidin A (111a) in 44% enantiomeric excess after transformation of the aldehyde to a methyl group and subsequent deprotection.<sup>82</sup> Using a similar reductive approach to that used on the bis-indolylpyrazine intermediate (131), an efficient synthesis of Dragmacidin B (111b) was achieved in 53% overall yield over two steps, as shown in Scheme 28. It should be noted that this was not an efficient method for synthesizing Dragmacidin C (111c), as the undesired isomer predominated and less than 5% yield of Dragmacidin C (111c) was isolated.<sup>83,84</sup>




Fig. 11 Chemical structures of Hamacanthins A–B (141a and 143a), Dihydrohamacanthins A–B (142a and 144a), and related debrominated natural products.

Recently, the first total synthesis of the more structurally complex Dragmacidin D (111d) was completed.<sup>85</sup> First, the iodinated indolic diamine intermediate (135) was synthesized in 11 linear steps from commercially available starting materials. Here, the desired stereoisomer of 135 was accessed *via* the use of Evan's oxazolidinone chiral auxiliary ((*S*)-3-acryloyl-4-phenyloxazolidin-2-one) and column chromatography.<sup>85</sup> After the key diamine intermediate (135) was synthesized, it was condensed with 6-bromo-1*H*-indole-3-oxo-acyl chloride and subsequently cyclized and oxidized to access 2-piperazinone intermediate (137) in 50% yield over multiple steps, as shown in Scheme 29. Then, 137 was protected to allow for selective  $\alpha$ -bromination, followed by a Staudinger reaction to access the  $\alpha$ -amino ester (139) in high yields. Treatment of this  $\alpha$ -amino ester (139) with pyrazole-1-carboxamide afforded a guanidine intermediate, which underwent subsequent reduction and cyclization to construct the 2-aminoimidazole moiety of Dragmacidin D in good yields. Deprotection then afforded Dragmacidin D (111d) in 50% yield. This synthesis revised the earlier stereochemical assignment that was based on biosynthetic considerations, assigning the absolute configuration as (*R*)-(+)-Dragmacidin D (111d). Furthermore, chiral HPLC-DAD methodology was developed and utilized to confirm, for the first time, that naturally occurring Dragmacidin D (111d) was isolated as either a racemate or a scalemic mixture (39% ee), which has prompted questions regarding the absolute configurations of Dragmacidins D–F (111d–f).<sup>85</sup>



Table 2 Hamacanthin class isolation data<sup>2,7,8,12,86,89</sup>


Compound	Configuration	Natural source
141a	<i>S</i>	<i>Hamacantha</i> , <i>Spongosorites</i> , <i>Disodermia calyx</i>
141b	<i>R</i>	<i>Spongosorites</i>
141c	<i>R</i>	<i>Spongosorites</i> , <i>Discodermia calyx</i>
141d	<i>S</i>	<i>Spongosorites</i>
143a	<i>S</i>	<i>Hamacantha</i> , <i>Spongosorites</i> , <i>Disodermia calyx</i>
143b	<i>R</i>	<i>Spongosorites</i> , <i>Discodermia calyx</i>
143c	<i>R</i>	<i>Spongosorites</i>
143d	<i>R</i>	<i>Spongosorites</i>
142a	3 <i>R</i> , 6 <i>R</i>	<i>Rhaphizia lacazei</i>
142b	3 <i>S</i> , 6 <i>R</i>	<i>Rhaphizia lacazei</i> , <i>Spongosorites</i>
142c	3 <i>S</i> , 6 <i>R</i>	<i>Rhaphizia lacazei</i> , <i>Spongosorites</i>
142d	3 <i>S</i> , 6 <i>R</i>	<i>Rhaphizia lacazei</i> , <i>Spongosorites</i>
144a	3 <i>S</i> , 5 <i>R</i>	<i>Rhaphizia lacazei</i> , <i>Spongosorites</i> , <i>Discodermia calyx</i>
144b	3 <i>S</i> , 5 <i>R</i>	<i>Rhaphizia lacazei</i> , <i>Spongosorites</i>
144c	3 <i>S</i> , 5 <i>R</i>	<i>Rhaphizia lacazei</i> , <i>Spongosorites</i>
144d	3 <i>S</i> , 5 <i>R</i>	<i>Spongosorites</i>


**2.4.2. Hamacanthins.** Another class of bis-indole alkaloids that are structurally related to the Dragmacidins are the Hamacanthins (**141a–d**, **142a–d**, **143a–d**, **144a–d**), which contain a 5,6-dihydro-2-pyridone or 2-piperazinone core connecting the two indole moieties, as shown in Fig. 11. The first of these natural products to be isolated were Hamacanthin A (**141a**) and Hamacanthin B (**143a**), which were isolated from *Hamacantha* marine sponge in 1994 by Gunasekera, *et. al.* These natural products were found to display antifungal activity.<sup>86</sup> In more recent years, the de-bromo and dihydro Hamacanthin analogues (**141b–d**, **142a–d**, **143b–d**, **144a–d**) have been isolated from various natural marine sources, as shown in Table 2. The configurations of these natural products are also indicated in Table 2, and many were later confirmed *via* total syntheses. Despite their structural similarities, the configurations of these Hamacanthins vary. For example, Hamacanthin A (**141a**) exists as the (*S*)-isomer, while its analogous mono de-bromo natural products (**141b** and **141c**) exist as the (*R*)-isomers, and its bis de-bromo analogue (**141d**) exists as the (*S*)-isomer (Table 2). Overall, natural products of the Hamacanthin class (**141a–d**, **142a–d**, **143a–d**, **143a–d**) have been shown to display antifungal, antibacterial, and cytotoxic activity.<sup>86</sup>

The first enantioselective total synthesis of the unnatural (*R*)-Hamacanthin A (**141a**) was completed in 2001 by Jiang, *et. al.* *via* the coupling of a 3-indolyl- $\alpha$ -oxo-acetyl chloride intermediate (**23b**) and 3-indolyl azidoethylamine intermediate (*R*)-(**146**), prior to an intramolecular aza-Wittig type cyclization to access (*R*)-Hamacanthin A (**141a**) in high yields, as shown in Scheme 30.<sup>87</sup> The 3-indolyl azidoethylamine intermediate was synthesized in four steps from *N*-tosylated-6-bromo-3-vinyl indole in high yields. The stereocenter of (**141a**) was established *via* a Sharpless asymmetric dihydroxylation reaction, followed by a stereospecific azidation. In spectroscopic comparison of the naturally isolated Hamacanthin A (**141a**) and the synthesized (*R*)-Hamacanthin A (**141a**), it was confirmed that the natural Hamacanthin A (**141a**) existed as the (*S*)-isomer.<sup>87,88</sup>

A year later, the same research team completed the first enantioselective total synthesis of Hamacanthin B (**143a**). As

shown in Scheme 30, this synthesis was completed *via* a similar approach as was previously discussed for (*R*)-Hamacanthin A (**141a**). Considering the established (*S*)-configuration of (**141a**), (*S*)-Hamacanthin B (**143a**) was synthesized. When compared to the naturally isolated Hamacanthin B (**143a**), the synthesized (*S*)-**143a** confirmed the configuration of the natural **143a** as the (*S*)-isomer.<sup>88</sup>

Scheme 30 Enantioselective total syntheses of Hamacanthins A and B (**141a** and **143a**).




Scheme 31 Enantioselective total syntheses of Hamacanthin A (141a) and Dihydrohamacanthin A–B (142a–b).

With the elucidation of the absolute configuration of (S)-Hamacanthin A (141a), the first enantioselective total synthesis of the desired (S)-Hamacanthin A (141a) was completed *via* deprotection and simultaneous inversion of the stereocenter of (R)-150 to access (S)-141a in 78% yield, as shown in Scheme 31. This allowed for additional confirmation that this was the correct configuration of the naturally occurring (S)-Hamacanthin A (141a). The synthetic approach toward (R)-150 was previously discussed in the Dragmacidin section (Scheme 27).<sup>81</sup> Also, using intermediate (R)-150, the first total syntheses of the unnatural (3S,6S)-*cis*-3,4-dihydrohamacanthin A (142a) and (3R,6S)-*trans*-3,4-dihydrohamacanthin A (142b) were both completed. The reduction of (R)-150 afforded 62% yield of (3S,6S)-*cis*-151 and 36% yield of (3R,6S)-*trans*-151. These 2-piperidone intermediates (151) were then deprotected *via* L-selectride to access (3S,6S)-*cis*-3,4-dihydrohamacanthin A (142a) and (3R,6S)-*trans*-3,4-dihydrohamacanthin A (142b) in 87% and 88% yields, respectively (Scheme 31). *Via* comparison of the naturally isolated *cis*-3,4-dihydrohamacanthin A (142a) and *trans*-3,4-dihydrohamacanthin A (142b) with the synthesized (3S,6S)-*cis*-142a and (3S,6S)-*trans*-142b, it was found that the configurations of these synthesized natural products did not match that of the isolated optical rotation data. Therefore, it was concluded that the absolute configurations of *cis*-3,4-dihydrohamacanthin A (142a) and *cis*-3,4-dihydrohamacanthin A (142a) are (3R,6R) and (3S,6R), respectively.<sup>81</sup> Additionally, racemic *cis*- and *trans*-3,4-dihydrohamacanthins can be accessed, albeit in low yields, *via* partial reduction of cyclized dipeptides (121 and 123), as was also discussed in the Dragmacidin section (Scheme 26).<sup>72</sup>

The first total syntheses of racemic 6'-debro-*trans*-3,4-dihydrohamacanthin A (142c) and the unnatural 6''-debro-*cis*-3,4-dihydrohamacanthin A (142e) were carried out *via* the condensation and subsequent cyclization of an indolic  $\alpha$ -amino


ketone intermediate (48) with an indolic keto-amide intermediate (153). After formation of this bis-indolylpyrazinone intermediate, it underwent reduction to access 6'-debro-*trans*-3,4-dihydrohamacanthin A (142c) and the unnatural 6''-debro-*cis*-3,4-dihydrohamacanthin A (142e) in 70% yield as a 1:1 mixture (Scheme 32). While it was not enantioselective, this method proved to be a very expeditious synthesis of these natural products.<sup>90</sup> This method also allowed for the first racemic total synthesis of 6''-debro-*cis*-3,4-dihydrohamacanthin B (144c) and 6',6''-debro-*cis*-3,4-dihydrohamacanthin B (144d). As shown in Scheme 32, this method was adapted to achieve the 3,5-disubstituted cyclized product by condensing and cyclizing an indolic oxo-acyl chloride intermediate (23a–b) with an indolic  $\alpha$ -amino ketone intermediate (48). In addition to being an efficient and high yielding route, this method was selective for the desired *cis*-isomers of 6''-debro-*cis*-3,4-dihydrohamacanthin B (144c) and 6',6''-debro-*cis*-3,4-dihydrohamacanthin B (144d), respectively.<sup>90</sup>

A similar bio-mimetic cyclization of a ketoamide (157) was proven efficient for the synthesis of both racemic Hamacanthin A (141a) and Hamacanthin B (143a). As shown in Scheme 33, to access Hamacanthin B (143a), nucleophilic attack of the primary amine on the indolic (C3) ketone and subsequent dehydration led to intermediate (II), which was deprotected to access 143a. On the other hand, nucleophilic attack of the primary amine on the amide carbonyl to form a five-membered ring intermediate (III), followed by a ring opening that resulted in a rearrangement of the original ketoamide to intermediate (IV). Cyclization of intermediate (IV) then led to Hamacanthin A (141a) after removal of protecting groups.<sup>90</sup> Through



Scheme 32 Enantioselective total syntheses of Debro-Dihydrohamacanthins (142c) and (144c–d).




Scheme 33 Total syntheses of Hamacanthins A and B (**141a**) (**143a**).Table 3 Cyclization conditions of keto–amide (**157**)

R'	R''	Solvent	Yield (V)	Yield (II)
Ts	H	DCE	42%	35%
Ts	H	1,4-Dioxane	30%	38%
Ts	H	EtOH	15%	75%
Ts	H	DMF	7%	46%
Ts	Ac	DCE	42%	55%
Ts	Ts	DCE	18%	68%


mechanistic study, it was determined that the ratio of **141a** : **143a** was heavily dependent on the identity of the solvent, and the protecting groups ( $\text{R}'$  and  $\text{R}''$ ), as indicated by the results shown in Table 3. In this case, more polar, protic solvents, such as ethanol, led to predominant formation of intermediate (II) while more non-polar solvents, such as dichloroethane (DCE), led to predominant formation of intermediate (V). In addition, the presence of stronger electron-withdrawing groups, such as a tosyl group, on the indole nitrogen led to predominant formation of intermediate (II) over intermediate (V) due to the resulting increased electrophilicity of the carbonyl group adjacent to the indole, making nucleophilic attack on this carbonyl preferable.<sup>90</sup>



In 2007, along with enantioselective total synthesis of (*S*)-Hamacanthins A and B (**141a** and **143a**), the first enantioselective total synthesis of *cis*-3,4-dihydrohamacanthin B (**144a**) was also completed.<sup>91</sup> As shown in Scheme 34, this synthesis

Scheme 34 First enantioselective total synthesis of Dihydrohamacanthin B (**144a**).

proceeded *via* the condensation of an indolic amino–alcohol intermediate (**162**) and an indolic oxo–acyl chloride intermediate (**23b**) to access a similar keto–amide intermediate (**163**), as was previously discussed. Subsequent cyclization of the keto–amide intermediate (**163**) and stereospecific reduction afforded (*3S,5R*)-*cis*-3,4-dihydrohamacanthin B (**144a**) in high yields. Here, the stereochemistry was set *via* the installation of an (*S*)-phenyloxazolidone chiral auxiliary (*S*)-**(159)**.<sup>91</sup>

In a slightly adapted, but very similar condensation of an indolic diamine intermediate (**164**) and an indolic oxo–acyl chloride intermediate (**23a–b**) and following cyclization, racemic Hamacanthin A (**141a**) and its related Debromohamacanthins (**141b–d**) were accessed in moderate to high yields, as shown in Scheme 35.<sup>92</sup> The indolic diamine intermediates (**164a–b**) were synthesized using the same method discussed previously in the Spongotine section (Scheme 5). At present,


Scheme 35 Total syntheses of Hamacanthin A (**141a**) and related Debromohamacanthins (**141b–d**).

Fig. 12 Chemical structures of Fellutanines A–C (**166a–c**).Scheme 36 First total synthesis of Fellutanine C (**166c**).

several debromo analogues of Hamacanthin B and Dihydrohamacanthin B have yet to be accessed *via* total synthesis.

**2.4.3. Fellutanines.** Fellutanines A–C (**166a–c**) were first isolated in 2000 by Kozlovsky *et al.* from the fungi *Penicillium fellutanum*. The 3,6-di-substituted-bis-indolyl-piperazine-2,5-dione structures of these natural products was elucidated *via* spectroscopic methods (Fig. 12). In addition, it was discovered that Fellutanine B (**166b**) contained an isopentenyl group on the 2-position of one of the indole moieties and Fellutanine C (**166c**) contained two isopentenyl substituents, one on the 2-position of each indole moiety.<sup>93</sup> The configuration of these Fellutanines A–C (**166a–c**) was initially reported as the *cis*-isomer, but this structure was later revised to the correct *trans*-isomer of the piperazine-2,5-dione core.<sup>93</sup> Much of the biological activity of these compounds is unknown, though some studies have shown they possess antibacterial activity, but no significant cytotoxic activity.<sup>93,94</sup>

Interestingly, the first total synthesis of Fellutanine C (**166c**) was completed before its first isolation, as it was an intermediate that was accessed in the 1995 total synthesis of another related fused bicyclic natural product, Gypsetin.<sup>95</sup> As is shown in Scheme 36, this total synthesis began with indolic C-2 reverse prenylation of *N*-phthaloyl-*L*-tryptophan methyl ester (**167**) *via* prenyl-9-BBN in high yield, followed by hydrazinolysis and subsequent Boc-protection and saponification to access intermediate (**170**) in high yields. Then, **170** and **168** were coupled to

Scheme 37 First total syntheses of Fellutanine A–B (**166a–b**).

access the desired *cis*-Fellutanine C (**166c**) in a very high 87% yield over three steps.<sup>95</sup>

In a similar approach using *L*-tryptophan analogues as starting materials, Fellutanine C (**166c**) was synthesized *via* the same intermediate (**168**) used previously, though here undergoing an expeditious dimerization and cyclization *via* pyrolysis conditions to access *cis*-Fellutanine C (**166c**) in 30% yield.<sup>96</sup> This proved to be an advantageous process in terms of step count by saving four steps compared to the previous synthesis, yet the yield decreased significantly in spite of this.

The first total synthesis of Fellutanine A (**166a**) was completed in 2008 in a similar method to that of Fellutanine C (**166c**). Here, a tryptophan analogue (**169**) and TrpOMe·HCl were condensed and subsequently cyclized to access the desired *cis*-Fellutanine A (**166a**) in 76% yield (Scheme 37).<sup>97</sup>

In addition to the previously discussed synthetic methods of accessing these Fellutanine natural products, many enzymatic biosynthetic methods have also been utilized over the years, using *L*-tryptophan as the starting material to access these molecules<sup>98,99</sup> Recently, a semi-total synthesis was developed and conducted to achieve all three natural products, Fellutanines A–C (**166a–c**), *via* the same route. As shown in Scheme 37, the same condensation and subsequent cyclization of tryptophan derivatives (**169**) and TrpOMe·HCl was conducted to access *cis*-Fellutanine A (**166a**) in 76% yield. Then, the enzymatic C2-reverse-prenylation of indole was performed *via* DMAPP prenyltransferase and aqueous MgCl<sub>2</sub> under slightly basic conditions, to access the mono-reverse prenylated *cis*-Fellutanine B (**166b**) as the major product in >70% yield. It is noteworthy to mention that, while not the major product, *cis*-Fellutanine C (**166c**) was also accessed *via* this method in 9% yield. The most significant achievement of this work was the first total synthesis of Fellutanine B (**166b**) and the development of a late stage selective reverse prenylation methodology of indole. It was also a significant that all three Fellutanines A–C (**166a–c**) could be accessed *via* this same route (Scheme 37).<sup>100</sup>

## 2.5 Pyridine and diazine linker moieties

**2.5.1. Hyrtinadine/Alocasin/Scalaridine.** Three structurally related bis-indole natural products with heterocyclic aromatic






Fig. 13 Chemical structures of Hyrtinadine A (172a), Alocasin A (172b), and Scalaridine A (173).


linker moieties were discovered between 2007 and 2013. The first of these was Hyrtinadine, A (172a), which was isolated in 2007 by Endo, *et. al.* from the Okinawan marine sponge *Hyrtios* sp.<sup>101</sup> This bis-indolyl-2,5-disubstituted pyrimidine structure was elucidated *via* spectroscopic methods (Fig. 13). Hyrtinadine A (172a) was also found to be highly cytotoxic towards murine Leukemia L1210 and human epidermoid carcinoma KB cell lines.<sup>101</sup> The next of these related natural products to be discovered was Alocasin A (172b), which was isolated in 2012 by Zhu, *et. al.* from the dried rhizomes of the herbaceous plant *Alocasia macrorrhiza*.<sup>102</sup> Alocasin A (172b) was reportedly the first heterocycle-linked bis-indole alkaloid isolated from a terrestrial source. As shown in Fig. 13, the chemical structure of (172b) has remarkable structural similarity to that of Hyrtinadine A (172a). However, the two indole moieties of Alocasin A (172b) are connected by a pyrazine linker moiety, rather than the pyrimidine of (172a). Much is unknown regarding the biological activity of Alocasin A (172b); however, it has been shown to

display weak antiproliferative activity against Hep-2 and Hep-G2 cell lines.<sup>102</sup> The most recent of these to be discovered was Scalaridine A (173), which was isolated in 2013 by Lee *et. al.* from the marine sponge *Scalarispongia* sp., along with the previously discussed Hyrtinadine A (172a).<sup>103</sup> This natural product (173) was determined to have a bis-indolyl-2,5-disubstituted pyridine structure. Interestingly, this is the only bis-indole alkaloid of its kind to contain a pyridine linker moiety. Much is also unknown regarding the biological activity of Scalaridine A (173), but much like its two aforementioned structural relatives, it also displayed significant cytotoxicity.<sup>103</sup>


The first of these natural products to be accessed *via* total synthesis was Hyrtinadine A (172b) in 2011, by Müller, *et. al.* As shown in Scheme 38, the first total synthesis of Hyrtinadine A (173) was achieved *via* sequential palladium-catalyzed Masuda borylation and double Suzuki cross-coupling reactions to install the two indole moieties on the 2- and 5-positions of the pyrimidine core. Subsequent de-methylation *via* BBr<sub>3</sub> achieved Hyrtinadine A (172a) in 78% yield.<sup>104</sup>

In 2015, the first total syntheses of Alocasin A (172b) and Scalaridine A (173) were completed *via* a similar borylation and subsequent double Suzuki coupling route as was used in the first total synthesis of Hyrtinadine A (172a), followed by de-methylation of the indolic hydroxyl groups to access Alocasin A (172b) and Scalaridine A (173) in high yields.<sup>105,106</sup>

One year later, a different approach to the total synthesis of all three natural products (172a, 172b, and 173), was conducted *via* successive palladium-catalyzed reactions; a Kosugi-Migita-




Scheme 38 First total syntheses of Hyrtinadine A (172a), Alocasin A (172b), and Scalaridine A (173).



Scheme 39 Total syntheses of Hyrtinadine A (172a), Alocasin A (172b), and Scalaridine A (173).





Scheme 40 Total syntheses of Alocasin A (172b) and Scalaridine A (173).

Stille cross coupling reaction to install the aromatic substituents on the heterocyclic linker, a reductive N-heterocyclization to form the indole moieties, and a final hydrogenolysis to access 172a, 172b, and 173 in high yields, as shown in Scheme 39.<sup>107</sup>

As can be concluded from the previously discussed syntheses of Hyrtinidine A (172a), Alocasin A (172b), and Scalaridine A (173), the common method of synthesis for these natural products is the use of palladium-catalyzed cross-coupling reactions to install the indole moieties on the aromatic N-heterocyclic cores.

In recent years, additional total syntheses of 172a–b and 173 have been reported using similar palladium-catalyzed cross coupling approaches.<sup>108–110</sup> A couple examples of these are shown in Scheme 40, such as the 2022 total synthesis of Scalaridine A (173) and the significantly expedited one-pot approach using a similar palladium-catalyzed methodology in the total synthesis of Alocasin A (172b). The latter achieved Alocasin A (172b) in 81% from the iodindole intermediate (183), using a three phase, one-pot method.<sup>111</sup>

### 3. Tris-indole alkaloids

Compared to their previously discussed bis-indole alkaloid counterparts, tris-indole alkaloids are rarer and more elusive in nature. However, in recent years, discovery and synthesis of these natural products has become more prevalent.

#### 3.1 Aromatic N-heterocyclic linker moieties

**3.1.1. Gelliusines.** Gelliusines A (186a) and B (186b) were first isolated as enantiomeric pairs in 1994 by Bifulco, *et. al.* from the deep-water marine sponge *Gellius* sp. (also known as *Orina* sp.).<sup>112</sup> The unique tris-indole chemical structure of these natural products, in which an indole core connects two




Fig. 14 Chemical structures of Gelliusines A–C (186a–c).

additional indole moieties at the C-2 and C-6 positions, was elucidated *via* spectroscopic methods, as shown in Fig. 14. In addition, Gelliusines A (186a) and B (186b) were determined to also contain three amine substituents. These amine substituents were of particular interest as it is hypothesized that they could contribute to favorable water-solubility of these natural products, which could be beneficial in bioactive applications. The absolute stereochemistry of the chiral centers of 186a and 186b was inconclusive *via* obtained data and, because Gelliusines A (186a) and B (186b) have yet to be accessed *via* total synthesis, their absolute configurations remain unknown. In terms of their biological activity, Gelliusines A (186a) and B (186b) were found to display cytotoxic activity, as well as anti-serotonin activity. The latter activity is unsurprising considering the structural similarities of Gelliusines A (186a) and B (186b) and serotonin.<sup>112</sup>

One year later, an additional structurally similar natural product of this class, Gelliusine C (186c) was isolated by the same group from the deep-water marine sponge *Gellius* sp. (also known as *Orina* sp.). As shown in Fig. 14, the chemical structure of Gelliusine C (186c) was determined to be a similar tris-indole alkaloid containing in indole core connecting two additional indole moieties, as well as containing three amine substituents. The main difference was, instead of the 2,6-substituted indole core of 186a–b, the indole core of Gelliusine C (186c) had the two additional indole moieties connected at the C2 and C4 positions. Similar to 186a–b, the absolute configuration of Gelliusine C (186c) was inconclusive *via* obtained data and, because Gelliusines C (186c) have yet to be accessed *via* total synthesis, its absolute configuration also remains unknown. In terms of their biological activity, Gelliusine C (186c) exhibited cytotoxic activity, as well as anti-serotonin activity.<sup>113</sup>





Fig. 15 Chemical structure of Tricepyridinium (187) and its related biological activity data.





Scheme 41 Total synthesis Tricepyridinium (187).

**3.1.2. Tricepyridinium.** Tricepyridinium (**187**) is a tris-indole alkaloid with a quaternary pyridinium core that was first isolated in 2017 by Abe *et al.* from a culture of *Escheichia coli* clone incorporating metagenomic libraries from the marine sponge *Discodermia calyx*. The 1,3,5-tri-substituted pyridinium core connecting the three indole moieties of Tricepyridinium (**187**) was elucidated *via* spectroscopic methods, as shown in Fig. 15.<sup>114</sup> Tricepyridinium (**187**) was found to display potent antibacterial activity, which is summarized in Fig. 15. Several bis-indole analogues of Tricepyridinium (**187**) were also synthesized and tested in this initial exploration of biological activity and **187** displayed more potent antibacterial activity than any of these analogues. Therefore, it was concluded that all three indole moieties of **187** were necessary for its potent antibacterial activity. In contrast, **187** did not display any cytotoxic activity against murine leukemic P388 cell line, while a bis-indole analogue of **187** lacking the indole moiety on the pyridinium nitrogen exhibited significant cytotoxic activity against this same cell line. This indicated that the cytotoxic activity of Tricepyridinium (**187**) was improved *via* removal of the indole in this position.<sup>114</sup>

The first total synthesis of Tricepyridinium (**187**) was completed in 2017 by Abe, *et al.* at the time of its isolation and structural elucidation to confirm its structure. As shown in Scheme 41, a bis-borylation of 3,5-dibromopyridine was completed to access intermediate **188**, followed by a subsequent palladium-catalyzed double Suzuki coupling to install two of the indole moieties on the pyridine ring. Boc deprotection and late-stage alkylation of the pyridine nitrogen *via* **191** to install the third indole moiety afforded Tricepyridinium (**187**) in high yields.<sup>114</sup>

In 2021, the total synthesis of Tricepyridinium (**187**) was completed *via* a similar approach as previously described.

However, the major difference in this approach was the palladium catalyzed Suzuki coupling reaction, in which the electronics of the coupling partners were swapped. In this case, an indolic boronic ester (**192**) was coupled with 3,5-dibromopyridine, similar to the previously discussed approaches toward Scalaridine A (**173**). This approach led to a slightly higher yield of intermediate (**189**) of 88% compared to the previous 73% yield. Then, **189** was deprotected and acylated *via* alkyl bromide **191** to access Tricepyridinium (**187**) in 59% yield over two steps (Scheme 41).<sup>115</sup>

## 3.2 Non-aromatic N-heterocyclic linker moieties

**3.2.1. Tulongicin.** Tulongicin (**193**) is a tri-indole alkaloid that was first isolated in 2017 by Liu *et al.* from *Topsentia sp.*, along with its previously discussed bis-indole alkaloid analogues, Dibromodeoxytopsentin (**1h**), Spongotine C (**2c**), and Dihydrospogotine C (**3**). Tulongicin (**193**) was structurally elucidated *via* spectroscopic methods. As shown in Fig. 16, Tulongicin (**193**) is comprised of an imidazoline core that links three brominated indole moieties. It is noteworthy to mention, **193** was the first marine alkaloid of its kind to contain the structurally complex bis-indole methane moiety connected to an imidazoline core. The absolute configuration of (4*S*)-**193** was determined *via* comparison of experimental and calculated circular dichroism (CD) data (MPW1PW91/6-31G(d,p)). The only known biological activity of **193** is its strong antibacterial activity toward *S. aureus* (MIC  $1.2 \mu\text{g mL}^{-1}$ ), its moderate anti-HIV activity (YU2: IC<sub>50</sub>  $3.9 \mu\text{M}$ , HxB2: IC<sub>50</sub>  $2.7 \mu\text{M}$ ), and its lack of cytotoxicity in mammalian cells. It is also noteworthy to mention that Tulongicin (**193**) has yet to be accessed *via* total synthesis.<sup>116</sup>

**3.2.2. Araisosamines.** The Araisosamines are arguably the most structurally complex of N-heterocyclic linked tris-indole alkaloid natural products that have been isolated to date. Araisosamines A–C (**194a–c**) were isolated in 2011 by Wei *et al.* from the marine sponge *Clathria (Thalysias) araiosa*.<sup>117</sup> As shown in Fig. 17, Araisosamines A and B (**194a–b**) contain three brominated indole moieties that are connected by cyclic guanidine and 2-imidazolinone linker moieties. The even more complex Araisosamine C (**194c**) contain three brominated indole moieties that are connected by a very complex fused and bridged cyclic guanidine core. These complex structures were elucidated *via* careful spectroscopic analysis. It is noteworthy to mention that the absolute configuration of these natural products is not known. The chemical structure of Araisosamine D falls outside




Fig. 16 Chemical structure of Tulongicin (193).








Fig. 17 Chemical structures of Araisosamines A–C (**194a–c**).

the scope of this review.<sup>117</sup> Interestingly, at the time of their isolation, Araisosamines A–C (**194a–c**) were not reported to exhibit any significant biological activity. However, several years later when some of these natural products were accessed *via* total synthesis, the Araisosamines were reported to display significant antibacterial activity against Gram-positive and Gram-negative bacteria, such as *S. aureus* and *E. coli*.<sup>118</sup>

Of these Araisosamine natural products, Araisosamine C (**194c**) is the only one to have been accessed *via* total synthesis. In 2016, Baran, *et al.* completed the first total synthesis *via* key



Scheme 42 First total synthesis of Araisosamine C (**194c**).



Scheme 43 Enantioselective total synthesis of Araisosamine C (**194c**).

guanidine installation and selective C–H functionalization steps driving toward a biomimetic final step to construct the complex core of **194c**. As is shown in Scheme 42, the first total synthesis of Araisosamine C (**194c**) began with formation of **195**, followed by deprotection and subsequent guanidinylation. Many guanidinylation reagents that were screened led to no reaction and it was hypothesized that the TFA group would impart adequate reactivity for the guanidinylation reagent to react with hindered or electron deficient amines. Reduction of the ester and subsequent cyclization led to **198** in 36% yield over three steps. The oxime intermediate (**199**) was then synthesized and subsequently reduced to the primary amine intermediate *via* SmI<sub>2</sub>. The reduction of the oxime (**199**) was very challenging because the oxime moiety is sterically encumbered by two adjacent indole groups and other functionalities such as the *N,O*-acetal or three aryl bromides are likely more prone toward reduction. After reaction of the resulting amine with *N,N*-di-Boc-*S*-methylisothiurea, the guanidine intermediate (**200**) was accessed in 53% over two steps.<sup>118</sup> As shown in Scheme 42, after deprotection and elimination of the methoxy group *via* acidic conditions and high temperatures, **201** was setup for the pivotal cyclization of the guanidine nitrogen and the fused cyclic imine/enamine to form the characteristic bridgehead of **194c**. After this sequence, Araisosamine C (**194c**) was accessed in a very high 81% yield.<sup>118</sup>

Since the absolute configuration of Araisosamine C (**194c**) was not known, the researchers adapted the previously discussed racemic path to **194c** to gain access to a stereoselective synthesis. As shown in Scheme 43, this was done by utilizing Ellman's Auxiliary to synthesize the optically active **203** in 76% yield as the favored diastereomer (d.r. = 7:1:2:0.5). This stereochemistry was then retained through to **205**, and using the same methodology as was previously discussed, the optically active (+)-Araisosamine C (**194c**) was synthesized, which was found to match the naturally isolated natural product based on optical rotation data.<sup>118</sup> It is noteworthy to mention that Araisosamines A and B (**194a–b**) have yet to be accessed *via* total synthesis.

## 4. Conclusions

To conclude, the examples discussed in this review summarize the wide range of bis- and tris-indole alkaloids containing *N*-



heterocyclic linker moieties that have been identified and isolated in recent years. These molecules exhibit potent biological activities, such as antibacterial, antiviral, cytotoxic, and anti-inflammatory activities. Natural products of this kind seem to share significant antibacterial activity overall. This could prove to be very advantageous in the future, as antibiotic resistance continues to be a major global issue. However, many of these previously discussed natural products have yet to be accessed *via* total synthesis, preventing their detailed biological evaluations. Development of synthetic methodologies to access these natural products and explore their promising biological activities will likely be of significant interest to the field in the future. It is also likely that the class of bis- and tris-indole natural products containing N-heterocyclic linker moieties will continue to expand as additional novel alkaloids are isolated.

## 5. Author contributions

Kyra R. Dvorak: conceptualization, writing original draft, writing, reviewing, and editing; Jetze, J. Tepe: supervision, reviewing, and editing.

## 6. Conflicts of interest

There are no conflicts to declare.

## 7. Acknowledgements

The authors gratefully acknowledge the National Institutes of Health, National Institutes of Aging R01 AG076994 for financial support.

## 8. Notes and references

- J. Kobayashi, T. Murayama, M. Ishibashi, S. Kosuge, M. Takamatsu, Y. Ohizumi, H. Kobayashi, T. Ohta, S. Nozoe and S. Takuma, Hyrtiosins A and B, New Indole Alkaloids from the Okinawan Marine Sponge Hyrtios Erecta, *Tetrahedron*, 1990, **46**(23), 7699–7702, DOI: [10.1016/S0040-4020\(01\)90065-1](https://doi.org/10.1016/S0040-4020(01)90065-1).
- B. Bao, Q. Sun, X. Yao, J. Hong, C.-O. Lee, H. Y. Cho and J. H. Jung, Bisindole Alkaloids of the Topsentin and Hamacanthin Classes from a Marine Sponge *Spongisorites* Sp, *J. Nat. Prod.*, 2007, **70**(1), 2–8, DOI: [10.1021/np060206z](https://doi.org/10.1021/np060206z).
- N. E. Golantsov, A. A. Festa, A. V. Karchava and M. A. Yurovskaya, Marine Indole Alkaloids Containing an 1-(Indol-3-yl)ethane-1,2-diamine Fragment (Review), *Chem. Heterocycl. Compd.*, 2013, **49**(2), 203–225, DOI: [10.1007/s10593-013-1238-9](https://doi.org/10.1007/s10593-013-1238-9).
- N. Kerru, L. Gummidi, S. Maddila, K. K. Gangu and S. B. Jonnalagadda, A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications, *Molecules*, 2020, **25**(8), 1909, DOI: [10.3390/molecules25081909](https://doi.org/10.3390/molecules25081909).
- K. Bartik, J.-C. Braekman, D. Daloz, C. Stoller, J. Huysecom, G. Vandevyver and R. Ottinger, Topsentins, New Toxic Bis-Indole Alkaloids from the Marine Sponge *Topsentia Genitrix*, *Can. J. Chem.*, 1987, **65**(9), 2118–2121, DOI: [10.1139/v87-352](https://doi.org/10.1139/v87-352).
- J. Shin, Y. Seo, K. W. Cho, J.-R. Rho and C. J. Sim, New Bis(Indole) Alkaloids of the Topsentin Class from the Sponge *Spongisorites Genitrix*, *J. Nat. Prod.*, 1999, **62**(4), 647–649, DOI: [10.1021/np980507b](https://doi.org/10.1021/np980507b).
- B. Bao, Q. Sun, X. Yao, J. Hong, C.-O. Lee, C. J. Sim, K. S. Im and J. H. Jung, Cytotoxic Bisindole Alkaloids from a Marine Sponge *Spongisorites* Sp, *J. Nat. Prod.*, 2005, **68**(5), 711–715, DOI: [10.1021/np049577a](https://doi.org/10.1021/np049577a).
- K.-B. Oh, W. Mar, S. Kim, J.-Y. Kim, M.-N. Oh, J.-G. Kim, D. Shin, C. J. Sim and J. Shin, Bis(Indole) Alkaloids as Sortase A Inhibitors from the Sponge *Spongisorites* Sp, *Bioorg. Med. Chem. Lett.*, 2005, **15**(22), 4927–4931, DOI: [10.1016/j.bmcl.2005.08.021](https://doi.org/10.1016/j.bmcl.2005.08.021).
- S. A. Morris and R. J. Andersen, Nitrogenous Metabolites from the Deep Water Sponge *Hexadella* Sp, *Can. J. Chem.*, 1989, **67**(4), 677–681, DOI: [10.1139/v89-102](https://doi.org/10.1139/v89-102).
- S. A. Morris and R. J. Andersen, Brominated Bis(Indole) Alkaloids from the Marine Sponge *Hexadella* Sp, *Tetrahedron*, 1990, **46**(3), 715–720, DOI: [10.1016/S0040-4020\(01\)81355-7](https://doi.org/10.1016/S0040-4020(01)81355-7).
- J. H. Hung, P. B. Shinde, J. Hong, Y. Liu and C. J. Sim, Secondary metabolites from a marine sponge *Discodermia calyx*, *Biochem. Syst. Ecol.*, 2007, **35**, 38.
- A. Casapullo, G. Bifulco, I. Bruno and R. Riccio, New Bisindole Alkaloids of the Topsentin and Hamacanthin Classes from the Mediterranean Marine Sponge *Rhaphisia Lacazei*, *J. Nat. Prod.*, 2000, **63**(4), 447–451, DOI: [10.1021/np9903292](https://doi.org/10.1021/np9903292).
- H.-B. Liu, G. Lauro, R. D. O'Connor, K. Lohith, M. Kelly, P. Colin, G. Bifulco and C. A. Bewley, Tulongicin, an Antibacterial Tri-Indole Alkaloid from a Deep-Water *Topsentia* Sp, *J. Nat. Prod.*, 2017, **80**(9), 2556–2560, DOI: [10.1021/acs.jnatprod.7b00452](https://doi.org/10.1021/acs.jnatprod.7b00452).
- H. Sun, K. Sun and J. Sun, Recent Advances of Marine Natural Indole Products in Chemical and Biological Aspects, *Molecules*, 2023, **28**(5), 2204, DOI: [10.3390/molecules28052204](https://doi.org/10.3390/molecules28052204).
- J. C. Braekman, D. Daloz, B. Moussiaux, C. Stoller and F. Deneubourg, Sponge Secondary Metabolites: New Results, *Pure Appl. Chem.*, 1989, **61**(3), 509–512, DOI: [10.1351/pac198961030509](https://doi.org/10.1351/pac198961030509).
- S. Tsujii, K. Rinehart and B. Topsentin, Dihydrodeoxytopsentin: Antiviral and Antitumor Bis(Indolyl)imidazoles from Caribbean Deep-Sea Sponges of the Family Halichondriidae, Structural and Synthetic Studies, *J. Org. Chem.*, 1988, **53**(23), 5446–5453.
- F. Y. Miyake, K. Yakushijin and D. A. Horne, A Concise Synthesis of Topsentin A and Nortopsentins B and D, *Org. Lett.*, 2000, **2**(14), 2121–2123, DOI: [10.1021/ol000124g](https://doi.org/10.1021/ol000124g).
- S. Achab, A Three-Component Coupling Approach to the Marine Bis-Indole Alkaloids: Topsentin, Deoxytopsentin and Bromotopsentin, *Tetrahedron Lett.*, 1996, **37**(31), 5503–5506, DOI: [10.1016/0040-4039\(96\)01148-3](https://doi.org/10.1016/0040-4039(96)01148-3).
- S. K. Mal, L. Bohé and S. Achab, Convenient Access to Bis-Indole Alkaloids. Application to the Synthesis of



- Topsentins, *Tetrahedron*, 2008, **64**(25), 5904–5914, DOI: [10.1016/j.tet.2008.04.045](https://doi.org/10.1016/j.tet.2008.04.045).
- 20 I. Kawasaki, H. Katsuma, Y. Nakayama and M. Yamashita, Total Synthesis of Topsentin, Antiviral and Antitumor Bis(Indolyl)Imidazole, *Heterocycles*, 1998, **48**(9), 1887–1901.
- 21 X. Guinchard, Y. Vallée and J.-N. Denis, Total Synthesis of Marine Sponge Bis(Indole) Alkaloids of the Topsentin Class, *J. Org. Chem.*, 2007, **72**(10), 3972–3975, DOI: [10.1021/jo070286r](https://doi.org/10.1021/jo070286r).
- 22 X. Guinchard, Y. Vallée and J. N. Denis, Total Syntheses of Brominated Marine Sponge Alkaloids, *Org. Lett.*, 2007, **9**(19), 3761–3764, DOI: [10.1021/ol701626m](https://doi.org/10.1021/ol701626m).
- 23 O. Ottoni, A. D. V. F. Neder, A. K. B. Dias, R. P. A. Cruz and L. B. Aquino, Acylation of Indole under Friedel–Crafts Conditions An Improved Method To Obtain 3-Acylindoles Regioselectively, *Org. Lett.*, 2001, **3**(7), 1005–1007, DOI: [10.1021/ol007056i](https://doi.org/10.1021/ol007056i).
- 24 K. Murai, M. Morishita, R. Nakatani, O. Kubo, H. Fujioka and Y. Kita, Concise Total Synthesis of (–)-Spongotone A, *J. Org. Chem.*, 2007, **72**(23), 8947–8949, DOI: [10.1021/jo701668s](https://doi.org/10.1021/jo701668s).
- 25 N. K. Garg, R. Sarpong and B. M. Stoltz, The First Total Synthesis of Dragmacidin D, *J. Am. Chem. Soc.*, 2002, **124**(44), 13179–13184, DOI: [10.1021/ja027822b](https://doi.org/10.1021/ja027822b).
- 26 S. Sakemi and H. H. Sun, Nortopsentins A, B, and C Cytotoxic and Antifungal Imidazolediybis[Indoles] from the Sponge Spongisorites Ruetzleri, *J. Org. Chem.*, 1991, **56**(13), 4304–4307, DOI: [10.1021/jo00013a044](https://doi.org/10.1021/jo00013a044).
- 27 H. Sun, S. Sakemi, S. Gunasekera, Y. Kashman, M. Lui, N. Burres and P. McCarthy, Bis-Indole Compounds Which Are Useful Antitumor and Antimicrobial Agents, *U.S. patent application*, US4970226A, 1990.
- 28 I. Mancini, G. Guella, F. Pietra, C. Debitus and J. Waikedre, From Inactive Nortopsentin D, a Novel Bis(Indole) Alkaloid Isolated from the Axinellid Sponge *Dragmacidon* Sp. from Deep Waters South of New Caledonia, to a Strongly Cytotoxic Derivative, *Helv. Chim. Acta*, 1996, **79**(8), 2075–2082, DOI: [10.1002/hlca.19960790804](https://doi.org/10.1002/hlca.19960790804).
- 29 S. Tilvi, C. Moriou, M.-T. Martin, J.-F. Gallard, J. Sorres, K. Patel, S. Petek, C. Debitus, L. Ermolenko and A. Al-Mourabit, Agelastatin E, Agelastatin F, and Benzoseptin C from the Marine Sponge *Agelas Dendromorpha*, *J. Nat. Prod.*, 2010, **73**(4), 720–723, DOI: [10.1021/np900539j](https://doi.org/10.1021/np900539j).
- 30 M. Shi, K. Kazuta, Y. Satoh and Y. Masaki, Synthesis and Investigation of C<sub>2</sub>-Symmetric Optically Active Pyrrolidinium Salts as Chiral Phase-Transfer Catalysts, *Chem. Pharm. Bull.*, 1994, **42**(12), 2625–2628, DOI: [10.1248/cpb.42.2625](https://doi.org/10.1248/cpb.42.2625).
- 31 J. Tan, Y. Chen, H. Li and N. Yasuda, Suzuki-Miyaura Cross-Coupling Reactions of Unprotected Haloimidazoles, *J. Org. Chem.*, 2014, **79**(18), 8871–8876, DOI: [10.1021/jo501326r](https://doi.org/10.1021/jo501326r).
- 32 K. L. Keel and J. J. Tepe, Total Synthesis of Nortopsentin D via a Late-Stage Pinacol-like Rearrangement, *Org. Lett.*, 2021, **23**(14), 5368–5372, DOI: [10.1021/acs.orglett.1c01681](https://doi.org/10.1021/acs.orglett.1c01681).
- 33 H. Sato, M. Tsuda, K. Watanabe and J. Kobayashi, Rhopaladins A–D, New Indole Alkaloids from Marine Tunicate Rhopalaea Sp, *Tetrahedron*, 1998, **54**(30), 8687–8690, DOI: [10.1016/S0040-4020\(98\)00470-0](https://doi.org/10.1016/S0040-4020(98)00470-0).
- 34 P. Fresneda, P. Molina and M. Sanz, The First Synthesis of the Bis(Indole) Marine Alkaloid Rhopaladin D, *Synlett*, 2000, **2000**(08), 1190–1192, DOI: [10.1055/s-2000-6746](https://doi.org/10.1055/s-2000-6746).
- 35 A. Fürstner, H. Krause and O. R. Thiel, Efficient Relay Syntheses and Assessment of the DNA-Cleaving Properties of the Pyrrole Alkaloid Derivatives Permethyl Storniamide A, Lycogalic Acid A Dimethyl Ester, and the Halitulins Core, *Tetrahedron*, 2002, **58**(32), 6373–6380, DOI: [10.1016/S0040-4020\(02\)00637-3](https://doi.org/10.1016/S0040-4020(02)00637-3).
- 36 J. S. Park, E. Cho, J.-Y. Hwang, S. C. Park, B. Chung, O.-S. Kwon, C. J. Sim, D.-C. Oh, K.-B. Oh and J. Shin, Bioactive Bis(Indole) Alkaloids from a Spongisorites Sp. Sponge, *Mar. Drugs*, 2020, **19**(1), 3, DOI: [10.3390/md19010003](https://doi.org/10.3390/md19010003).
- 37 P. E. Lecoq de Boisbaudran, *Compt. Rendus*, 1882, (94), 55–59.
- 38 N. Durán and C. F. M. Menck, *Chromobacterium Violaceum*: A Review of Pharmacological and Industrial Perspectives, *Crit. Rev. Microbiol.*, 2001, **27**(3), 201–222, DOI: [10.1080/20014091096747](https://doi.org/10.1080/20014091096747).
- 39 L. H. Yang, H. Xiong, O. O. Lee, S.-H. Qi and P.-Y. Qian, Effect of Agitation on Violacein Production in *Pseudoalteromonas Luteoviolacea* Isolated from a Marine Sponge, *Let. Appl. Microbiol.*, 2007, **44**(6), 625–630, DOI: [10.1111/j.1472-765X.2007.02125.x](https://doi.org/10.1111/j.1472-765X.2007.02125.x).
- 40 S. Yada, Y. Wang, Y. Zou, K. Nagasaki, K. Hosokawa, I. Osaka, R. Arakawa and K. Enomoto, Isolation and Characterization of Two Groups of Novel Marine Bacteria Producing Violacein, *Mar. Biotechnol.*, 2008, **10**(2), 128–132, DOI: [10.1007/s10126-007-9046-9](https://doi.org/10.1007/s10126-007-9046-9).
- 41 S. Hakvåg, E. Fjærvik, G. Klinkenberg, S. E. Borgos, K. Josefsen, T. Ellingsen and S. Zotchev, Violacein-Producing *Collimonas* Sp. from the Sea Surface Microlayer of Coastal Waters in Trøndelag, Norway, *Mar. Drugs*, 2009, **7**(4), 576–588, DOI: [10.3390/md7040576](https://doi.org/10.3390/md7040576).
- 42 P. Jiang, H. Wang, C. Zhang, K. Lou and X.-H. Xing, Reconstruction of the Violacein Biosynthetic Pathway from *Duganella* Sp. B2 in Different Heterologous Hosts, *Appl. Microbiol. Biotechnol.*, 2010, **86**(4), 1077–1088, DOI: [10.1007/s00253-009-2375-z](https://doi.org/10.1007/s00253-009-2375-z).
- 43 T. Hoshino, Violacein and Related Tryptophan Metabolites Produced by *Chromobacterium Violaceum*: Biosynthetic Mechanism and Pathway for Construction of Violacein Core, *Appl. Microbiol. Biotechnol.*, 2011, **91**(6), 1463–1475, DOI: [10.1007/s00253-011-3468-z](https://doi.org/10.1007/s00253-011-3468-z).
- 44 M. Durán, A. N. Ponezi, A. Faljoni-Alario, M. F. S. Teixeira, G. Z. Justo and N. Durán, Potential Applications of Violacein: A Microbial Pigment, *Med. Chem. Res.*, 2012, **21**(7), 1524–1532, DOI: [10.1007/s00044-011-9654-9](https://doi.org/10.1007/s00044-011-9654-9).
- 45 J. A. Ballantine, C. B. Barrett, R. J. S. Beer, S. Eardley, A. Robertson, B. L. Shaw and T. H. Simpson, The Chemistry of Bacteria Part VII the Structure of Violacein, *J. Chem. Soc.*, 1958, **5**, 755–760.



- 46 G. Wille and W. Steglich, A Short Synthesis of the Bacterial Pigments Violacein and Deoxyviolacein, *Synthesis*, 2001, **2001**(05), 0759–0762, DOI: [10.1055/s-2001-12776](https://doi.org/10.1055/s-2001-12776).
- 47 M. T. Petersen and T. E. Nielsen, Tandem Ring-Closing Metathesis/Isomerization Reactions for the Total Synthesis of Violacein, *Org. Lett.*, 2013, **15**(8), 1986–1989, DOI: [10.1021/ol400654r](https://doi.org/10.1021/ol400654r).
- 48 W. Steglich, B. Steffan, L. Kopanski and G. Eckhardt, Indolfarbstoffe aus Fruchtkörpern des Schleimpilzes *Arcyria denudata*, *Angew. Chem.*, 1980, **92**(6), 463–464, DOI: [10.1002/ange.19800920607](https://doi.org/10.1002/ange.19800920607).
- 49 S. Nakatani, A. Naoe, Y. Yamamoto, T. Yamauchi, N. Yamaguchi and M. Ishibashi, Isolation of Bisindole Alkaloids That Inhibit the Cell Cycle from Myxomycetes *Arcyria ferruginea* and *Tubifera casparyi*, *Bioorg. Med. Chem. Lett.*, 2003, **13**(17), 2879–2881, DOI: [10.1016/S0960-894X\(03\)00592-4](https://doi.org/10.1016/S0960-894X(03)00592-4).
- 50 A. P. Monte, D. Marona-Lewicka, N. V. Cozzi and D. E. Nichols, Synthesis and Pharmacological Examination of Benzofuran, Indan, and Tetralin Analogs of 3,4-(Methylenedioxy)Amphetamine, *J. Med. Chem.*, 1993, **36**(23), 3700–3706, DOI: [10.1021/jm00075a027](https://doi.org/10.1021/jm00075a027).
- 51 D. Mochly-Rosen and L. M. Kauvar, *Adv. Pharmacol.*, 1998, **44**, 91–145.
- 52 K. Kaniwa, M. A. Arai, X. Li and M. Ishibashi, Synthesis, Determination of Stereochemistry, and Evaluation of New Bisindole Alkaloids from the Myxomycete *Arcyria ferruginea*: An Approach for Wnt Signal Inhibitor, *Bioorg. Med. Chem. Lett.*, 2007, **17**(15), 4254–4257, DOI: [10.1016/j.bmcl.2007.05.033](https://doi.org/10.1016/j.bmcl.2007.05.033).
- 53 M. Brenner, H. Rexhausen, B. Steffan and W. Steglich, Synthesis of *Arcyriarubin b* and Related Bisindolylmaleimides, *Tetrahedron*, 1988, **44**(10), 2887–2892, DOI: [10.1016/S0040-4020\(88\)90025-7](https://doi.org/10.1016/S0040-4020(88)90025-7).
- 54 M. M. Faul, K. A. Sullivan and L. L. Winneroski, A General Approach to the Synthesis of Bisindolylmaleimides: Synthesis of Staurosporine Aglycone, *Synthesis*, 1995, (12), 1511–1516, DOI: [10.1055/s-1995-4146](https://doi.org/10.1055/s-1995-4146).
- 55 X. Mei, J. Wang, Z. Zhou, S. Wu, L. Huang, Z. Lin and Q. Ling, Diarylmaleic Anhydrides: Unusual Organic Luminescence, Multi-Stimuli Response and Photochromism, *J. Mater. Chem.*, 2017, **5**(8), 2135–2141, DOI: [10.1039/C6TC05519B](https://doi.org/10.1039/C6TC05519B).
- 56 Q. Guo, W.-F. Deng, J.-L. Xiao, P.-C. Shi, J.-L. Li, Z.-X. Zhou and C. Ji, Synthesis, Single Crystal X-Ray Analysis and Vibrational Spectral Studies of 3,4-Di(1H-Indol-3-yl)-1H-Pyrrole-2,5-dione, *J. Mol. Struct.*, 2023, **1281**, 135103, DOI: [10.1016/j.molstruc.2023.135103](https://doi.org/10.1016/j.molstruc.2023.135103).
- 57 R. Fröde, C. Hinze, I. Josten, B. Schmidt, B. Steffan and W. Steglich, Isolation and Synthesis of 3,4-Bis(Indol-3-yl)Pyrrole-2,5-Dicarboxylic Acid Derivatives from the Slime Mould *Lycogala epidendrum*, *Tetrahedron Lett.*, 1994, **35**(11), 1689–1690, DOI: [10.1016/0040-4039\(94\)88320-3](https://doi.org/10.1016/0040-4039(94)88320-3).
- 58 T. Hashimoto, Y. Akiyo, K. Akazawa, S. Takaoka, M. Tori and Y. Asakawa, Three Novel Dimethyl Pyrroledicarboxylate, Lycogarubins A-C, from the Myxomycetes *Lycogala epidendrum*, *Tetrahedron Lett.*, 1994, **35**(16), 2559–2560, DOI: [10.1016/S0040-4039\(00\)77170-X](https://doi.org/10.1016/S0040-4039(00)77170-X).
- 59 T. Nishizawa, S. Grüşchow, D.-H. E. Jayamaha, C. Nishizawa-Harada and D. H. Sherman, Enzymatic Assembly of the Bis-Indole Core of Rebecamycin, *J. Am. Chem. Soc.*, 2006, **128**(3), 724–725, DOI: [10.1021/ja056749x](https://doi.org/10.1021/ja056749x).
- 60 W. Chen, Z. Feng, X. He, Q. Zhao and Q. Liang, Design and Synthesis of 3,4-Diarylpyrrole Analogues as Potent Topoisomerase Inhibitors, *Med. Chem.*, 2018, **14**(5), 485–494, DOI: [10.2174/1573406414666180226164049](https://doi.org/10.2174/1573406414666180226164049).
- 61 C. Hinze, A. Kreipl, A. Terpin and W. Steglich, Synthesis of Simple 3,4-Diarylpyrrole-2,5-Dicarboxylic Acids and Lukianol A by Oxidative Condensation of 3-Arylpyruvic Acids with Ammonia, *Synthesis*, 2007, **2007**(04), 608–612, DOI: [10.1055/s-2007-965876](https://doi.org/10.1055/s-2007-965876).
- 62 N. Zhou, T. Xie, L. Liu and Z. Xie, Cu/Mn Co-Oxidized Cyclization for the Synthesis of Highly Substituted Pyrrole Derivatives from Amino Acid Esters: A Strategy for the Biomimetic Syntheses of Lycogarubin C and Chromopyrrolic Acid, *J. Org. Chem.*, 2014, **79**(13), 6061–6068, DOI: [10.1021/jo500740w](https://doi.org/10.1021/jo500740w).
- 63 X. Zheng, Y. Li, M. Guan, L. Wang, S. Wei, Y. Li, C. Chang and Z. Xu, Biomimetic Total Synthesis of the Spiroindimicin Family of Natural Products, *Angew. Chem., Int. Ed.*, 2022, **61**(38), e202208802, DOI: [10.1002/anie.202208802](https://doi.org/10.1002/anie.202208802).
- 64 L. Fu and G. W. Gribble, Total Synthesis of Lycogarubin C Utilizing the Kornfeld–Boger Ring Contraction, *Tetrahedron Lett.*, 2010, **51**(3), 537–539, DOI: [10.1016/j.tetlet.2009.11.085](https://doi.org/10.1016/j.tetlet.2009.11.085).
- 65 J. S. Oakdale and D. L. Boger, Total Synthesis of Lycogarubin C and Lycogalic Acid, *Org. Lett.*, 2010, **12**(5), 1132–1134, DOI: [10.1021/ol100146b](https://doi.org/10.1021/ol100146b).
- 66 K. A. McArthur, S. S. Mitchell, G. Tsueng, A. Rheingold, D. J. White, J. Grodberg, K. S. Lam and B. C. M. Potts, Lynamycins A–E, Chlorinated Bisindole Pyrrole Antibiotics from a Novel Marine Actinomycete, *J. Nat. Prod.*, 2008, **71**(10), 1732–1737, DOI: [10.1021/np800286d](https://doi.org/10.1021/np800286d).
- 67 W. Zhang, L. Ma, S. Li, Z. Liu, Y. Chen, H. Zhang, G. Zhang, Q. Zhang, X. Tian, C. Yuan, S. Zhang, W. Zhang, C. Zhang and A.-E. Indimicins, Bisindole Alkaloids from the Deep-Sea-Derived *Streptomyces* Sp. SCSIO 03032, *J. Nat. Prod.*, 2014, **77**(8), 1887–1892, DOI: [10.1021/np500362p](https://doi.org/10.1021/np500362p).
- 68 I. Sigala, G. Ganidis, S. Thysiadis, A. L. Zografos, T. Giannakouros, V. Sarli and E. Nikolakaki, Lynamycin D an Antimicrobial Natural Product Affects Splicing by Inducing the Expression of SR Protein Kinase 1, *Bioorg. Med. Chem.*, 2017, **25**(5), 1622–1629, DOI: [10.1016/j.bmc.2017.01.025](https://doi.org/10.1016/j.bmc.2017.01.025).
- 69 Z. Zhang, S. Ray, L. Imlay, L. T. Callaghan, H. Niederstrasser, P. L. Mallipeddi, B. A. Posner, D. M. Wetzel, M. A. Phillips and M. W. Smith, Total Synthesis of (+)-Spiroindimicin A and Congeners Unveils Their Antiparasitic Activity, *Chem. Sci.*, 2021, **12**(30), 10388–10394, DOI: [10.1039/D1SC02838C](https://doi.org/10.1039/D1SC02838C).
- 70 S. Kohmoto, Y. Kashman, O. J. McConnell, K. L. Rinehart, A. Wright and F. Koehn, Dragmacidin, a New Cytotoxic



- Bis(Indole) Alkaloid from a Deep Water Marine Sponge, Dragmacidon Sp, *J. Org. Chem.*, 1988, **53**(13), 3116–3118, DOI: [10.1021/jo00248a040](https://doi.org/10.1021/jo00248a040).
- 71 E. Fahy, B. C. M. Potts, D. J. Faulkner and K. Smith, 6-Bromotryptamine Derivatives from the Gulf of California Tunicate *Didemnum Candidum*, *J. Nat. Prod.*, 1991, **54**(2), 564–569, DOI: [10.1021/np50074a032](https://doi.org/10.1021/np50074a032).
- 72 T. Kawasaki, K. Ohno, H. Enoki, Y. Umemoto and M. Sakamoto, Syntheses of Bis(Indolyl)-Piperazine Alkaloids, Dragmacidin B and C, and Dihydrohamacanthin A, *Tetrahedron Lett.*, 2002, **43**(23), 4245–4248, DOI: [10.1016/S0040-4039\(02\)00771-2](https://doi.org/10.1016/S0040-4039(02)00771-2).
- 73 R. J. Capon, F. Rooney, L. M. Murray, E. Collins, A. T. R. Sim, J. A. P. Rostas, M. S. Butler and A. R. Carroll, Dragmacidins: New Protein Phosphatase Inhibitors from a Southern Australian Deep-Water Marine Sponge, *Spongosorites* Sp, *J. Nat. Prod.*, 1998, **61**(5), 660–662, DOI: [10.1021/np970483t](https://doi.org/10.1021/np970483t).
- 74 A. Cutignano, G. Bifulco, I. Bruno, A. Casapullo, L. Gomez-Paloma, R. Riccio and F. Dragmacidin, A New Antiviral Bromoindole Alkaloid from the Mediterranean Sponge *Halicortex* Sp, *Tetrahedron*, 2000, **56**(23), 3743–3748, DOI: [10.1016/S0040-4020\(00\)00281-7](https://doi.org/10.1016/S0040-4020(00)00281-7).
- 75 N. K. Garg, D. D. Caspi and B. M. Stoltz, The Total Synthesis of (+)-Dragmacidin F, *J. Am. Chem. Soc.*, 2004, **126**(31), 9552–9553, DOI: [10.1021/ja046695b](https://doi.org/10.1021/ja046695b).
- 76 K. S. Feldman and P. Ngermmeesri, Total Synthesis of (±)-Dragmacidin E, *Org. Lett.*, 2011, **13**(20), 5704–5707, DOI: [10.1021/ol202535f](https://doi.org/10.1021/ol202535f).
- 77 A. Wright, K. Killday, D. Chakrabarti, E. Guzmán, D. Harmody, P. McCarthy, T. Pitts, S. Pomponi, J. Reed, B. Roberts, C. Rodrigues Felix, K. Rohde and G. Dragmacidin, a Bioactive Bis-Indole Alkaloid from a Deep-Water Sponge of the Genus *Spongosorites*, *Mar. Drugs*, 2017, **15**(1), 16, DOI: [10.3390/md15010016](https://doi.org/10.3390/md15010016).
- 78 B. Jiang, J. M. Smallheer, C. Amaral-Ly and M. A. Wuonola, Total Synthesis of (+)-Dragmacidin: A Cytotoxic Bis(Indole)Alkaloid of Marine Origin, *J. Org. Chem.*, 1994, **59**(22), 6823–6827, DOI: [10.1021/jo00101a051](https://doi.org/10.1021/jo00101a051).
- 79 C. R. Whitlock and M. P. Cava, A Total Synthesis of Dragmacidin B, *Tetrahedron Lett.*, 1994, **35**(3), 371–374, DOI: [10.1016/0040-4039\(94\)85056-9](https://doi.org/10.1016/0040-4039(94)85056-9).
- 80 T. Kawasaki, H. Enoki, K. Matsumura, M. Ohyama, M. Inagawa and M. Sakamoto, Total Synthesis of Dragmacidin A via Inolyglycines, *Org. Lett.*, 2000, **2**(19), 3027–3029, DOI: [10.1021/ol006394g](https://doi.org/10.1021/ol006394g).
- 81 C. G. Yang, J. Wang, X. X. Tang and B. Jiang, Asymmetric Aminohydroxylation of Vinyl Indoles: A Short Enantioselective Synthesis of the Bisindole Alkaloids Dihydrohamacanthin A and Dragmacidin A, *Tetrahedron: Asymmetry*, 2002, **13**(4), 383–394, DOI: [10.1016/S0957-4166\(02\)00111-8](https://doi.org/10.1016/S0957-4166(02)00111-8).
- 82 C. G. Yang, J. Wang, X. X. Tang and B. Jiang, Asymmetric Aminohydroxylation of Vinyl Indoles: a Short Enantioselective Synthesis of the Bisindole Alkaloids Dihydrohamacanthin and Dragmacidin A, *Tetrahedron: Asymmetry*, 2002, **13**, 383, DOI: [10.1016/S0957-4166\(02\)00111-8](https://doi.org/10.1016/S0957-4166(02)00111-8).
- 83 F. Y. Miyake, K. Yakushijin and D. A. Horne, A Facile Synthesis of Dragmacidin B and 2,5-Bis(6'-Bromo-3'-Indolyl)Piperazine, *Org. Lett.*, 2000, **2**(20), 3185–3187, DOI: [10.1021/ol000197o](https://doi.org/10.1021/ol000197o).
- 84 F. Tonsiengsom, F. Y. Miyake, K. Yakushijin and D. A. Horne, *Synthesis*, 2006, 49.
- 85 F. Zhang, B. Wang, P. Prasad, R. J. Capon and Y. Jia, Asymmetric Total Synthesis of (+)-Dragmacidin D Reveals Unexpected Stereocomplexity, *Org. Lett.*, 2015, **17**(6), 1529–1532, DOI: [10.1021/acs.orglett.5b00327](https://doi.org/10.1021/acs.orglett.5b00327).
- 86 S. P. Gunasekera, P. J. McCarthy and M. Kelly-Borges, Hamacanthins A and B, New Antifungal Bis Indole Alkaloids from the Deep-Water Marine Sponge, *Hamacantha* Sp, *J. Nat. Prod.*, 1994, **57**(10), 1437–1441, DOI: [10.1021/np50112a014](https://doi.org/10.1021/np50112a014).
- 87 B. Jiang, C.-G. Yang and J. Wang, Enantioselective Synthesis for the (–)-Antipode of the Pyrazinone Marine Alkaloid, Hamacanthin A, *J. Org. Chem.*, 2001, **66**(14), 4865–4869, DOI: [10.1021/jo010265b](https://doi.org/10.1021/jo010265b).
- 88 B. Jiang, C.-G. Yang and J. Wang, Enantioselective Synthesis of Marine Indole Alkaloid Hamacanthin B, *J. Org. Chem.*, 2002, **67**(4), 1396–1398, DOI: [10.1021/jo0108109](https://doi.org/10.1021/jo0108109).
- 89 J. H. Jung, P. B. Shinde, J. Hong, Y. Liu and C. J. Sim, Secondary Metabolites from a Marine Sponge *Discodermia Calyx*, *Biochem. Syst. Ecol.*, 2007, **35**(1), 48–51, DOI: [10.1016/j.bse.2006.08.008](https://doi.org/10.1016/j.bse.2006.08.008).
- 90 T. Kawasaki, T. Kouko, H. Totsuka and K. Hiramatsu, Synthesis of Marine Bisindole Alkaloids, Hamacanthins A and B through Intramolecular Transamidation–Cyclization, *Tetrahedron Lett.*, 2003, **44**(49), 8849–8852, DOI: [10.1016/j.tetlet.2003.09.184](https://doi.org/10.1016/j.tetlet.2003.09.184).
- 91 K. Higuchi, R. Takei, T. Kouko and T. Kawasaki, Total Synthesis of Marine Bisindole Alkaloid (+)- *Cis*-Dihydrohamacanthin B, *Synthesis*, 2007, **2007**(5), 669–674, DOI: [10.1055/s-2007-965907](https://doi.org/10.1055/s-2007-965907).
- 92 X. Guinchard, Total Syntheses of Brominated Marine Sponge Alkaloids, *Org. Lett.*, 2007, **9**(19), 3761–3764, DOI: [10.1021/ol701626m](https://doi.org/10.1021/ol701626m).
- 93 A. G. Kozlovsky, N. G. Vinokurova, V. M. Adanin, G. Burkhardt, H. M. Dahse and U. Gräfe, New Diketopiperazine Alkaloids from *Penicillium Fellutanum*, *J. Nat. Prod.*, 2000, **63**(5), 698–700, DOI: [10.1021/np9903853](https://doi.org/10.1021/np9903853).
- 94 H. Hayashi, Bioactive Alkaloids of Fungal Origin, *Studies in Natural Products Chemistry*, Elsevier, 2005, vol. 32, pp. 549–609, DOI: [10.1016/S1572-5995\(05\)80064-X](https://doi.org/10.1016/S1572-5995(05)80064-X).
- 95 J. M. Schkeryantz, J. C. G. Woo and S. J. Danishefsky, Total Synthesis of Gypsetin, *J. Am. Chem. Soc.*, 1995, **117**(26), 7025–7026, DOI: [10.1021/ja00131a035](https://doi.org/10.1021/ja00131a035).
- 96 J. M. Schkeryantz, J. C. G. Woo, P. Siliphaivanh, K. M. Depew and S. J. Danishefsky, Total Synthesis of Gypsetin, Deoxybrevianamide E, Brevianamide E, and Tryprostatin B: Novel Constructions of 2,3-Disubstituted Indoles, *J. Am. Chem. Soc.*, 1999, **121**(51), 11964–11975, DOI: [10.1021/ja9925249](https://doi.org/10.1021/ja9925249).



- 97 K. B. Joshi and S. Verma, Participation of Aromatic Side Chains in Diketopiperazine Ensembles, *Tetrahedron Lett.*, 2008, **49**(27), 4231–4234, DOI: [10.1016/j.tetlet.2008.04.156](https://doi.org/10.1016/j.tetlet.2008.04.156).
- 98 X. Cheng and L. Ma, Enzymatic Synthesis of Fluorinated Compounds, *Appl. Microbiol. Biotechnol.*, 2021, **105**(21), 8033–8058.
- 99 H. Usuki, Y. Yamamoto, J. Arima, M. Iwabuchi, S. Miyoshi, T. Nitoda and T. Hatanaka, Peptide Bond Formation by Aminolysin-A Catalysis: A Simple Approach to Enzymatic Synthesis of Diverse Short Oligopeptides and Biologically Active Puromycins, *Org. Biomol. Chem.*, 2011, **9**(7), 2327, DOI: [10.1039/c0ob00403k](https://doi.org/10.1039/c0ob00403k).
- 100 S. P. Kelly, V. V. Shende, A. R. Flynn, Q. Dan, Y. Ye, J. L. Smith, S. Tsukamoto, M. S. Sigman and D. H. Sherman, Data Science-Driven Analysis of Substrate-Permissive Diketopiperazine Reverse Prenyltransferase NotF: Applications in Protein Engineering and Cascade Biocatalytic Synthesis of (–)-Eurotiumin A, *J. Am. Chem. Soc.*, 2022, **144**(42), 19326–19336, DOI: [10.1021/jacs.2c06631](https://doi.org/10.1021/jacs.2c06631).
- 101 T. Endo, M. Tsuda, J. Fromont and J. Kobayashi, Hyrtinadine A, a Bis-Indole Alkaloid from a Marine Sponge, *J. Nat. Prod.*, 2007, **70**(3), 423–424, DOI: [10.1021/np060420n](https://doi.org/10.1021/np060420n).
- 102 L. Zhu, C. Chen, H. Wang, W. Ye and G. Zhou, Indole Alkaloids from *Alocasia Macrorrhiza*, *Chem. Pharm. Bull.*, 2012, **60**(5), 670–673, DOI: [10.1248/cpb.60.670](https://doi.org/10.1248/cpb.60.670).
- 103 Y.-J. Lee, D.-G. Lee, H. S. Rho, V. B. Krasokhin, H. J. Shin, J. S. Lee and H.-S. Lee, Cytotoxic 5-Hydroxyindole Alkaloids from the Marine Sponge *Scalarispongia* Sp.: Cytotoxic 5-Hydroxyindole Alkaloids from the Marine Sponge *Scalarispongia* Sp, *J. Heterocycl. Chem.*, 2013, **50**(6), 1400–1404, DOI: [10.1002/jhet.1599](https://doi.org/10.1002/jhet.1599).
- 104 B. O. A. Tasch, E. Merkul and T. J. J. Müller, One-Pot Synthesis of Diazine-Bridged Bisindoles and Concise Synthesis of the Marine Alkaloid Hyrtinadine A, *Eur. J. Org. Chem.*, 2011, **2011**(24), 4532–4535, DOI: [10.1002/ejoc.201100680](https://doi.org/10.1002/ejoc.201100680).
- 105 S. H. Kim and J. Sperry, Synthesis of Alocasin A, *J. Nat. Prod.*, 2015, **78**(12), 3080–3082, DOI: [10.1021/acs.jnatprod.5b00853](https://doi.org/10.1021/acs.jnatprod.5b00853).
- 106 S. H. Kim and J. Sperry, Synthesis of Scalaridine A, *Tetrahedron Lett.*, 2015, **56**(43), 5914–5915, DOI: [10.1016/j.tetlet.2015.09.033](https://doi.org/10.1016/j.tetlet.2015.09.033).
- 107 N. H. Ansari and B. C. G. Söderberg, Short Syntheses of the Indole Alkaloids Alocasin A, Scalaridine A, and Hyrtinadine A-B, *Tetrahedron*, 2016, **72**(29), 4214–4221, DOI: [10.1016/j.tet.2016.05.057](https://doi.org/10.1016/j.tet.2016.05.057).
- 108 G. Ranjani and R. Nagarajan, Insight into Copper Catalysis: *In Situ* Formed Nano Cu<sub>2</sub>O in Suzuki–Miyaura Cross-Coupling of Aryl/Indolyl Boronates, *Org. Lett.*, 2017, **19**(15), 3974–3977, DOI: [10.1021/acs.orglett.7b01669](https://doi.org/10.1021/acs.orglett.7b01669).
- 109 M. Kruppa, G. A. Sommer and T. J. J. Müller, Concise Syntheses of Marine (Bis)Indole Alkaloids Meridianin C, D, F, and G and Scalaridine A *via* One-Pot Masuda Borylation-Suzuki Coupling Sequence, *Molecules*, 2022, **27**(7), 2233, DOI: [10.3390/molecules27072233](https://doi.org/10.3390/molecules27072233).
- 110 J. Dong, H. Ma, B. Wang, S. Yang, Z. Wang, Y. Li, Y. Liu and Q. Wang, Discovery of Hyrtinadine A and Its Derivatives as Novel Antiviral and Anti-Phytopathogenic-Fungus Agents, *Molecules*, 2022, **27**(23), 8439, DOI: [10.3390/molecules27238439](https://doi.org/10.3390/molecules27238439).
- 111 N. Rehberg, G. A. Sommer, D. Drießen, M. Kruppa, E. T. Adeniyi, S. Chen, L. Wang, K. Wolf, B. O. A. Tasch, T. R. Ioerger, K. Zhu, T. J. J. Müller and R. Kalscheuer, Nature-Inspired (Di)Azine-Bridged Bisindole Alkaloids with Potent Antibacterial *In Vitro* and *In Vivo* Efficacy against Methicillin-Resistant *Staphylococcus Aureus*, *J. Med. Chem.*, 2020, **63**(21), 12623–12641, DOI: [10.1021/acs.jmedchem.0c00826](https://doi.org/10.1021/acs.jmedchem.0c00826).
- 112 G. Bifulco, I. Bruno, L. Minale, R. Riccio, A. Calignano and C. Debitus, (±)-Gelliusines A and B, Two Diastereomeric Brominated Tris-Indole Alkaloids from a Deep Water New Caledonian Marine Sponge (Gellius or Orina Sp.), *J. Nat. Prod.*, 1994, **57**(9), 1294–1299, DOI: [10.1021/np50111a020](https://doi.org/10.1021/np50111a020).
- 113 G. Bifulco, I. Bruno, R. Riccio, J. Lavayre and G. Bourdy, Further Brominated Bis- and Tris-Indole Alkaloids from the Deep-Water New Caledonian Marine Sponge Orina Sp, *J. Nat. Prod.*, 1995, **58**(8), 1254–1260, DOI: [10.1021/np50122a017](https://doi.org/10.1021/np50122a017).
- 114 M. Okada, T. Sugita, C. P. Wong, T. Wakimoto and I. Abe, Identification of Pyridinium with Three Indole Moieties as an Antimicrobial Agent, *J. Nat. Prod.*, 2017, **80**(4), 1205–1209, DOI: [10.1021/acs.jnatprod.6b01152](https://doi.org/10.1021/acs.jnatprod.6b01152).
- 115 M. A. Garrison, A. R. Mahoney and W. M. Wuest, Tricepyridinium-inspired QACs Yield Potent Antimicrobials and Provide Insight into QAC Resistance, *Chem. Med. Chem.*, 2021, **16**(3), 463–466, DOI: [10.1002/cmdc.202000604](https://doi.org/10.1002/cmdc.202000604).
- 116 H.-B. Liu, G. Lauro, R. D. O'Connor, K. Lohith, M. Kelly, P. Colin, G. Bifulco and C. A. Bewley, Tulongicin, an Antibacterial Tri-Indole Alkaloid from a Deep-Water *Topsentia* Sp, *J. Nat. Prod.*, 2017, **80**(9), 2556–2560, DOI: [10.1021/acs.jnatprod.7b00452](https://doi.org/10.1021/acs.jnatprod.7b00452).
- 117 X. Wei, N. M. Henriksen, J. J. Skalicky, M. K. Harper, T. E. Cheatham, C. M. Ireland and R. M. Van Wagoner, Araisamines A–D: Tris-Bromoindole Cyclic Guanidine Alkaloids from the Marine Sponge *Clathria (Thalysias) Araisosa*, *J. Org. Chem.*, 2011, **76**(14), 5515–5523, DOI: [10.1021/jo200327d](https://doi.org/10.1021/jo200327d).
- 118 M. Tian, M. Yan and P. S. Baran, 11-Step Total Synthesis of Araisamines, *J. Am. Chem. Soc.*, 2016, **138**(43), 14234–14237, DOI: [10.1021/jacs.6b09701](https://doi.org/10.1021/jacs.6b09701).

